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Abstract 
 
This thesis is comprised of two parts. The first part investigates a novel therapy, vagus nerve 
stimulation, for hypertension and hypertension-induced heart disease. Hypertension impacts over 
1 billion people worldwide, and clinical management is challenging. Left uncontrolled, high blood 
pressure can significantly increase the risk of cardiovascular events. The majority of hypertensive 
patients are treated with anti-hypertensive drugs to control blood pressure, but many limitations 
exist including resistant hypertension, inability to tolerate therapy, and non-compliance with the 
medication regime. For these patients, an alternative approach is needed to control blood pressure. 
Recently, the imbalance in the autonomic nervous system, evident in hypertension, has been the 
target of novel device-based therapies such as vagus nerve stimulation. The main goal of this 
research is to evaluate the efficacy of vagus nerve stimulation to treat hypertension and 
hypertension-induced heart disease. This thesis investigates the impact of vagus nerve stimulation 
on disease progression, survival, and cardiovascular remodeling in Dahl salt-sensitive hypertensive 
rats. Overall, the results of this work provide evidence for the beneficial therapeutic effects of vagus 
nerve stimulation in hypertension and motivate future studies to optimize therapy parameters and 
further understand therapeutic mechanisms.    
 
The second part of this thesis focuses on atrial fibrillation and the evaluation of new mapping 
techniques for improving rotor localization for ablation procedures. Currently, success rates for 
ablation procedures for non-paroxysmal atrial fibrillation are low and require repeat procedures or 
a lifetime of pharmacological agents to reduce the risk of stroke. Improved signal processing 
techniques for mapping electrical activity in the atrium can help further our understanding of the 
generation and maintenance of atrial fibrillation and ultimately improve ablation procedure success 
rates and terminate the arrhythmia. The main goal of this work was to validate new signal 
processing techniques – multiscale frequency, kurtosis, Shannon entropy, and multiscale entropy – 
to identify regions of abnormal electrical activity. The results of this work demonstrate improved 
accuracy of these novel techniques in mapping rotors in cardiac arrhythmias and motivates further 
studies evaluating more complex arrhythmias and human intracardiac electrograms. 
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Chapter 1 
 
Introduction 
 
Hypertension (HTN) and atrial fibrillation (AF) are two very prevalent conditions with over 1 
billion and 33.5 million people affected worldwide, respectively [1, 2] with these numbers only 
predicted to rise with the aging population. In the case of HTN, the most common treatment 
approach is antihypertensive medications. Despite a large body of research demonstrating efficacy 
of pharmaceuticals, almost half of the patient population does not have controlled blood pressure, 
which increases their risk of cardiovascular and cerebral events [3]. In AF, patients are often treated 
using ablation to isolate the pulmonary veins. For patients with paroxysmal AF, this approach has 
the highest success rates with termination of the arrhythmia in over 70% of patients [4]. However 
for those with persistent AF, pulmonary vein isolation ablation procedures are only successful in 
21-22% of patients, often requiring repeat procedures or prescription medications to limit the 
associated risk if the arrhythmia is unable to be terminated [5, 6]. New therapies are needed to help 
overcome limitation associated with the current clinical approach to help improve patient outcomes.  
HTN poses a unique challenge to clinicians to treat as appropriate therapy requires a 
combination of controlling blood pressure and associated risks while also accounting for 
comorbidities, drug resistance, non-compliance, and intolerance. Recently, research has turned to 
modulation of the autonomic nervous system (ANS) as a potential therapy for HTN and 
hypertension-induced heart disease (HHD). A large body of literature exists demonstrating the 
imbalance in the ANS, with sympathetic hyperactivity driving the pathophysiology of HTN [7]. 
Novel device-based therapies, such as vagus nerve stimulation (VNS), baroreceptor activation 
therapy, and renal nerve denervation, target this imbalance to reduce global sympathetic outflow 
and enhance parasympathetic tone. Rebalancing the ANS can have numerous beneficial effects in 
hypertensive patients including blood pressure control, cardioprotection, and anti-inflammatory 
response. However, research is needed to investigate novel therapies and evaluate the efficacy in 
controlling blood pressure and addressing adverse cardiovascular remodeling.  
 AF is a prevalent condition worldwide and often can develop as a result of unmanaged high 
blood pressure and the subsequent cardiac remodeling. One key challenge today is understanding 
the spatial organization of the arrhythmia. Multiple theories exist, including multiple wavelet 
theory and focal sources (i.e. rotors). However, to date, there is still a lack of understanding around 
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the substrate responsible for the initiation and maintenance of the arrhythmia due to its complex 
evolution and inconsistencies between patients. Thus, properly targeting the responsible tissue and 
terminating the arrhythmia is challenging. One treatment option for patients with AF is ablation to 
isolate the pulmonary veins. However, for many patients the arrhythmia is not terminated after a 
single procedure, requiring repeat ablations or to continue pharmacological agents to minimize risk 
of long-term complications such as of stroke. Improving mapping techniques for ablation therapies 
can help advance our understanding of the underlying spatial organization of the arrhythmia and 
improve localization of ablation targets to ultimately improve procedure outcomes.  
The present dissertation is presented in two parts. Part 1 (Chapters 2-6) is the main contribution 
of this thesis and aims to evaluate the efficacy of a novel device-based therapy, VNS, in treating 
HTN and HHD. Part 2 (Chapters 7-9) investigates novel mapping techniques in their ability to 
locate rotors in cardiac arrhythmias and its associated implications for clinical electrophysiological 
mapping in AF. 
 
1.1 PART 1 
Chapter 2 provides detailed background on HTN management and the development of new 
therapies. This chapter discusses pharmaceutical options for patients, the limitations with current 
approaches, and the recent development of novel device-based therapies targeting the ANS 
imbalance present in HTN. Chapter 2 provides background on VNS and the current experimental 
and clinical findings relevant to HTN and associated cardiovascular disease.  
Chapter 3 details the experimental study investigating the effects of VNS in Dahl salt-sensitive 
(DSS) rats. This initial study investigated the effects of four weeks of VNS therapy in hypertensive 
rats to investigate safety and efficacy. In-vivo and ex-vivo effects of VNS in HTN are presented, 
providing evidence for VNS as an effective therapy. 
Further experiments were performed to evaluate chronic effects of VNS in DSS hypertensive 
rats on long-term survival and relevant cardiovascular and hemodynamic parameters and are 
presented in Chapters 4 and 5. Chapter 4 details the experimental methods and results of the 
survival study investigating the impact of VNS therapy on long-term survival, blood pressure, heart 
rate, autonomic tone, and cardiac structural properties. Chapter 5 provides the methods and results 
for acute evaluation of individual episodes of VNS therapy to better understand the cardiovascular 
and hemodynamic changes that occur during low-level, intermittent vagal stimulation. 
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Chapter 6 summarizes the main findings and contributions of this thesis, providing evidence 
for the efficacy of VNS to treat HTN and HHD. In addition, recommendations for future work and 
scientific investigations are discussed.  
 
1.2 PART 2 
Chapter 7 provides the background information for the second part of the thesis, investigating 
novel mapping techniques for rotor identification in cardiac arrhythmias, including AF. Chapter 7 
describes AF and the current clinical management and treatment. Several key limitations with the 
current approaches to guide ablation procedures are discussed. In addition, mapping techniques to 
better locate areas of abnormal electrical activity that may help lead to new therapeutic targets for 
patients with AF are presented.  
In Chapter 8, the experimental results for new signal processing techniques to map rotors in 
cardiac arrhythmias are presented. Four novel mapping techniques – multiscale frequency, kurtosis, 
Shannon entropy, and multiscale entropy – are evaluated using arrhythmias captured during ex-
vivo animal experiments driven by rotors on the epicardial surface. The accuracy of the rotor 
identification was compared to the traditional mapping technique, dominant frequency analysis, as 
well as phase movies derived from optical mapping recordings. Further analysis quantified the 
performance of these techniques under simulated clinical limitations.   
Chapter 9 summarizes the key findings from my work in AF and mapping rotors. This chapter 
also presents future work and clinical translation.  
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Part 1 
 
Investigating novel device-based therapy, vagus 
nerve stimulation, for hypertension and hypertension-
induced heart disease 
 
OBJECTIVE 
The objective of Part 1 of my dissertation is to demonstrate the efficacy of a novel therapy, 
vagus nerve stimulation, for the treatment of hypertension and hypertension-induced heart disease. 
Through direct activation of the parasympathetic nervous system, vagus nerve stimulation provides 
a novel approach to target the imbalance in the autonomic nervous system, which is known to play 
a critical role in the pathogenesis of hypertension. The acute and chronic effects of low-level, 
intermittent vagus nerve stimulation are demonstrated through two studies investigating the 
progression of hypertension in Dahl salt-sensitive rats. In-vivo and ex-vivo results provide evidence 
of the beneficial impact of vagus nerve stimulation on several key aspects of hypertension including 
long-term survival, blood pressure control, and heart rate, autonomic tone, along with 
electrophysiological and structural cardiac properties.    
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Chapter 2 
 
Background 
 
2.1 INTRODUCTION 
This chapter provides the background on hypertension (HTN) and hypertension-induced heart 
disease (HHD), and also summarizes experiments performed to investigate the efficacy of a novel 
device-based therapy, vagus nerve stimulation (VNS), to treat various cardiovascular and metabolic 
diseases. Chapter 2 discusses the current prevalence and impact of HTN while also presenting the 
current standard of care for patients with HTN and limitations with the current approach, which 
have motivated investigations into new therapies.  
2.2 HYPERTENSION & HYPERTENSION-INDUCED HEART DISEASE 
HTN, or high blood pressure (BP), affects over 1 billion people around the world and is the 
leading risk factor for cardiovascular disease (CVD), stroke, and global disease burden [1, 8]. With 
the aging population, this number is expected to continue to climb, reaching over 1.5 billion by 
2025 [9]. In the United States alone, over 75 million adults are diagnosed with HTN and results in 
an annual cost of $42.9 billion, with over $20 billion spent on antihypertensive medication [10]. 
Left uncontrolled, the rise in BP can result in target organ damage in the myocardium, brain, 
vasculature, and kidney (Figure 2.1) [8, 11-13].  
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Figure 2.1 Major complications associated with hypertension. 
 
Cardiovascular remodeling and the development of CVD is a major concern for patients with 
HTN and includes a wide range of abnormalities such as left ventricular hypertrophy, systolic and 
diastolic dysfunction, arrhythmias and heart failure (HF) [14]. Common structural cardiac 
remodeling due to HTN is shown in Figure 2.2 [15]. In fact, 51% of adults with CVD have HTN, 
and 40.6% of CVD-related deaths have been attributed to HTN [10]. In addition, HTN is present 
in 75% of patients with chronic HF [16]. These electrical and structural cardiac changes occur early 
in HTN and ultimately increase the hearts susceptibility to the development of atrial and ventricular 
arrhythmias as well as increases in the risk of death, making early detection, treatment, and 
management of HTN critical.  
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Figure 2.2 Common cardiac remodeling including atrial dilation left ventricular hypertrophy 
occurring in hypertension-induced heart disease (HHD; right) in comparison with the normal, 
healthy heart (left). Adapted from Berk et al. 2007 [15]. 
 
The classic progression to HHD is through left ventricular wall thickening in compensatory 
response to elevated BP to minimize the stress on the walls of the heart, shown in Figure 2.3 [17]. 
This hypertrophy can result from numerous alterations including increased cardiomyocyte size, 
changes in the extracellular matrix, and accumulation of fibrosis, both interstitial and perivascular. 
The increase in left ventricular mass can than lead to left ventricular dilation and reduced ejection 
fraction as the heart “transitions to failure” [14].   
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Figure 2.3 The role of hypertension in the development of heart failure. Adapted from Vasan & 
Levy, 1996 [17]. 
 
Recently, the American College of Cardiology and American Heart Association updated the 
guidelines for detection, prevention, management, and treatment of high BP in the hopes of 
attaining lower, controlled BP levels and reducing the associated cardiovascular complications. The 
new classifications are shown in Table 2.1 [3]. This change in standards increased the number of 
HTN diagnoses by 31.1 million adult in the United States alone, increasing the percent of adults 
with HTN from 32% to 46% [18]. It has been shown that with an increase in 20 mmHg systolic 
blood pressure (SBP) or 10 mmHg diastolic blood pressure (DBP), the risk of death from CVD and 
stroke doubles [1, 3]. Decreasing BP down to normotensive levels can greatly diminish the patient’s 
risk of a cardiovascular event.  
 
Table 2.1 New hypertension classifications 
Classification Systolic Blood Pressure Diastolic Blood Pressure 
Normal 120 mmHg 80 mmHg 
Elevated 120-129 mmHg < 80 mmHg 
Stage 1 HTN 130-139 mmHg 80-89 mmHg 
Stage 2 HTN >140 mmHg > 90 mmHg 
 
2.3 CURRENT TREATMENT OPTIONS 
Currently, the primary basis for treating HTN is with pharmacological agents in addition to 
lifestyle changes including diet and exercise. Currently, there are a large variety of pharmaceutical 
options available to treat patients. The primary classes of antihypertensive drugs used to treat HTN 
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include thiazide diuretics, angiotensin converting enzymes (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) and calcium channel blockers (CCBs). A summary of classes of HTN medications 
are included in Table 2.2 [9].  
 
Table 2.2 Classes of antihypertensive drugs and their associated mechanism of action 
Class of Antihypertensive 
Medication 
Mechanisms of Action 
Diuretics 
Inhibits the reabsorption of sodium, preventing fluid 
retention 
ACE Inhibitors 
Inhibits the conversion of the inactive angiotensin I to the 
active angiotensin II 
ARBs 
Blocks angiotensin II from binding to its receptor, 
preventing it from causing vasoconstriction and fluid 
retention.  
Renin Inhibitors Inhibits the conversion of angiotensin to angiotensin I 
CCBs 
Prevents the entry of calcium into the vascular smooth 
muscles, resulting in vasodilation and reduced contractility 
in the vasculature 
Beta-blockers 
Blocks beta-1 adrenergic receptors, resulting in slower heart 
rate, decreased contractility, and reduced cardiac output 
Inhibits renin release, resulting in reduced angiotensin II 
production 
Alpha-blockers 
Blocks alpha-1 adrenorecpetors which are responsible for 
vasoconstriction in vascular smooth muscles 
Direct Vasodilators Relaxes smooth muscles, primarily arterioles 
 
These medications can be used individually or in combination to achieve controlled BP levels. 
Despite a large body of research demonstrating the efficacy of these antihypertensive medications, 
there still exists a large portion of the hypertensive population who do not reach their target BP 
levels. Although the percentage of adults with HTN who have achieved controlled BP levels has 
increased from 49.3% in 2009 to 55.2% in 2012 [3], still approximately half of the patients with 
HTN do not reach target BP levels. Several key factors contribute to this alarming statistic including 
resistance, compliance, cost, side effects, and physician inertia [19].  
Patients are considered to have resistant HTN if they are unable to achieve BP values of 140/90 
mmHg or less while on 3 or more antihypertensive drugs or those who are able to control BP, but 
require at least 4 antihypertensive drugs. The exact prevalence of resistant HTN is unknown, but 
studies estimate between 10-30% of hypertensive patients have resistant HTN. This number is 
expected to increase due to the combination of the new standard of care of HTN increasing the 
number of patients diagnosed with HTN and decreasing the target blood pressure levels from 
140/90 to 130/80 mmHg [3, 20, 21]. The large range in prevalence demonstrated in studies is due 
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to the difficulty in true diagnosis of resistant HTN, as numerous hypertensive patients have 
uncontrolled BP due to noncompliance, intolerance, and inadequate treatment regime.  
Noncompliance is a prominent challenge clinician’s face when trying to reach target BP for the 
hypertensive patient population. Recently, it was reported that 40% of patients discontinued 
antihypertensive medications within the first year of treatment [22]. Further follow up revealed that 
by 10 years after the start of treatment, less than 40% of patients continued with their prescribed 
antihypertensive medications [23].  
New therapeutic options are necessary for hypertensive patients to address the limitations of 
current treatment options. An optimal therapy for HTN would address the inappropriate rise in BP 
while also addressing adverse cardiovascular remodeling and associated risks. In addition, new 
therapies that are able to reduce costs and side effects while also encouraging compliance can help 
increase the number of patients reaching target BP levels and ultimately reduce their risk of cerebral 
and cardiovascular events.  
 
2.4 DEVICE-BASED THERAPIES 
Recently, novel device-based therapies have been investigated for treating HTN. These 
therapies target the imbalance in the autonomic nervous system (ANS) present in hypertensive 
patients, which manifests as an inappropriate increase in sympathetic nervous activity and a 
withdrawal of parasympathetic nervous activity [7]. Increased sympathetic nerve activity plays a 
critical role in the development, maintenance and acceleration of HTN [7, 20]. Several studies have 
demonstrated that this imbalance is present even before BP reaches hypertensive values, and the 
increase in sympathetic activity continues to rise in parallel as HTN advances [7, 24, 25]. One 
hypothesis for the rise in sympathetic activity is the excessive adrenergic response, which initially 
increases BP variability, but over time may contribute to a sustained increase in BP. Another 
proposed mechanism contributing to an overactive sympathetic nervous system (SNS) is through 
the reduction in the influence or function of arterial baroreceptors [7]. Targeting this imbalance in 
the ANS, through either the parasympathetic or sympathetic branch, may provide a novel therapy 
for HTN to prevent its progression and possibly reverse any adverse remodeling associated with a 
sustained increase in BP. 
Several therapies being investigated for the treatment of HTN and HHD directly target the over 
activity in the SNS with the goal of inhibiting efferent and afferent sympathetic nervous activity 
(Figure 2.4). These therapies include baroreceptor activation therapy (BAT) and renal denervation 
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(RDNx). In contrast, vagus nerve stimulation (VNS) stimulates the parasympathetic branch with 
the goal of rebalancing the ANS through a combination of efferent and afferent parasympathetic 
activation and resulting inhibition of sympathetic activity.  
 
 
Figure 2.4 Device-based therapies targeting the sympathetic branch (BAT & RDNx) and 
parasympathetic branch (VNS) of the autonomic nervous system as a therapy for HTN. Figures 
adapted from Klabunde, 2011 [26] and Fischell et al. 2016 [27]. 
 
2.4.1 Baroreceptor Activation Therapy 
Baroreceptors play a critical role in short- and long-term BP control. BAT directly stimulates 
the carotid baroreceptors to increase firing rate of baroreceptors as their function is often altered in 
HTN resulting in a rise the homeostatic BP set point and reduced sensitivity to blood pressure 
fluctuations [28, 29]. One hypothesis of impaired or altered function of baroreceptors is due to 
stiffening of the arterial walls in response to increased BP leading to a diminished response from 
the baroreceptors. Electrically stimulating the baroreceptors results in increased parasympathetic 
activity and decreased sympathetic outflow which is the primary mechanism for BP reduction 
(Figure 2.5) [30].  
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Figure 2.5 Mechanisms of BAT for the treatment of resistant HTN. Adapted from Yoruk et al. 
2016 [30]. 
 
BAT has been investigated in several key clinical trials. The DEBut-HT trial implanted 45 
patients with BAT and demonstrated a significant drop in BP which was reported at 6 months, 1 
year, and 2 years post-implant [31]. However, during this study, there were 8 procedure or device-
related serious adverse events. The Rheos Pivotal trial, a larger clinical trial with 265 patients with 
resistant HTN, failed to meet several efficacy and safety endpoints [32]. These clinical results 
motivated further advancements in technology and improvements in the baroreflex activation 
device including a smaller but longer lasting battery, smaller electrodes, and a reduction in the 
number of electrodes (Figure 2.6). These modifications will hopefully address the limitations 
revealed by these trials, and subsequently reduce the number of serious adverse events. With this 
new technology, a small clinical trial was performed with 30 patients showing a reduction in BP at 
6 months and a reduction in complications [33]. This therapy and newer technology will be further 
evaluated in the upcoming Barostim Hypertension Pivotal Trial. 
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Figure 2.6 Comparison of the original CVRx Rheos device (left) and the newer Barostim neo 
(right) technology for BAT. Adapted from Yoruk et al. 2016 [30]. 
 
2.4.2 Renal Denervation 
Renal nerves are responsible, in part, for the development and progression of HTN. The 
efferent renal nerves innervating the kidney are responsible for the modulation of renin release, 
sodium reabsorption, and vascular resistance [34, 35]. Many pharmaceutical agents target one or 
more of these components. However with RDNx, the advantage is to provide localized therapy 
acting on the kidney and renal nerve directly as opposed to a global therapy which may lead to 
undesirable side effects. RDNx applies energy to ablate the afferent and efferent sympathetic 
nerves. Ablating efferent renal nerves results in a reduction in renin release, sodium reabsorption, 
and vascular resistance, ultimately lowering BP. The ablation of afferent nerves are also suspected 
to play a role in controlling BP through a reduction in global sympathetic activity (Figure 2.7) [34, 
36-38]. 
 
14 
 
 
Figure 2.7 Role of renal afferent and efferent nerves in the pathogenesis of HTN. Adapted from 
Booth et al. 2015 [39]. 
 
Several clinical trials have been performed to evaluate this therapy in humans. SYMPLICITY 
HTN-1 and SYMPLICITY HTN-2 demonstrated reductions in BP in resistant HTN patients [40-
42]. However, the third clinical trial, SYMPLICITY HTN-3, failed to meet its efficacy endpoint 
[43, 44] due to numerous pitfalls including failure to properly perform the procedure and potential 
confounding factors from changes in medication and compliance [45]. The result of SYMPLICITY 
HTN-3 highlighted one of the major limitations of the RDNx procedure, which is the lack of a 
method to confirm the completeness and effectiveness of the ablation procedure. In addition, 
another limitation in achieving complete RDNx is the secondary branches of the renal artery, which 
also play a role in the pathogenesis of HTN. The outcome of SYMPLICITY HTN-3 made the field 
hesitate and question the validity of the technique. However, with the recent SPYRAL HTN Global 
Clinical Trial using a new ablation catheter design and reporting positive effects 3 months post-
operative [46], research into RDNx therapy for HTN has been rejuvenated. Further studies will 
continue with the improved catheter design (Figure 2.8) and physician training implemented in the 
newest SPYRAL trial in hopes of achieving more complete and consistent ablation results [47].   
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Figure 2.8 Catheter ablation technologies for the SYMPLICITY HTN-3 trial (top) and the new 
design for the SPYRAL HTN ON-MED trial (bottom). Adapted from Patel et al. 2014 [48] and 
Kandzari et al. 2016 [47]. 
 
2.4.3 Vagus Nerve Stimulation  
Another treatment approach for HTN is to target the parasympathetic branch of the ANS 
through stimulation of the vagus nerve. VNS is applied at the cervical level and is hypothesized to 
work through numerous mechanisms including afferent signaling suppressing sympathetic 
activation and efferent signaling enhancing cardiac parasympathetic tone (Figure 2.9). With the 
direct innervation to the heart, while also playing a major role in BP control, modulation of vagal 
activity is hypothesized to provide efficacious therapy for HTN, allowing patients to achieve target 
BP levels while also treating HTN-associated cardiovascular complications.  
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Figure 2.9 Proposed mechanisms of VNS therapy through efferent and afferent nerve activation. 
 
This therapy is the focus of my thesis in investigating its efficacy to treat HTN and HHD. The 
following sections will go into detail on the anatomy of the vagus nerve, clinical applications, and 
experimental findings of VNS demonstrating its potential to provide an effective therapy for HTN 
and HHD.  
 
2.5 VAGUS NERVE STIMULATION 
2.5.1 Vagus Nerve Anatomy & Physiology 
The vagus nerve is the tenth cranial nerve (CN X), a complex, parasympathetic nerve 
originating from the medulla. Named the “great wandering protector” [49], the vagus innervates 
numerous major organs in the body and is involved in the autonomic, cardiovascular, endocrine, 
gastrointestinal, immune, and respiratory systems making it the most extensively distributed cranial 
nerve (Figure 2.10) [50, 51].  
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Figure 2.10 Anatomy of the vagus nerve. Adapted from Netter, 2016 [52]. 
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Approximately 80-90% of the fibers in the vagus nerve are sensory, or afferent, fibers 
communicating to the brain with the remaining 10-20% of fibers in the vagus nerve being efferent 
fibers, transmitting signals from the brain to the viscera [53]. Vagal afferent fibers carry sensory 
information from various organs, including the heart, which are then integrated and interpreted by 
the central nervous system (CNS). The CNS then sends out appropriate sympathetic and 
parasympathetic motor signals on efferent fibers to adjust organ function and maintain homeostasis 
[51, 54, 55]. Specifically, in the case of the heart, when activated, the vagus nerve has a 
cardioinhibitory effect, reducing heart rate and contractility [54, 56]. This effect is mediated 
through efferent signaling directly to the myocardium. Both the right and left vagus nerves carry 
cardiac efferent fibers, but anatomical studies in dogs suggest that those on the right side 
preferentially supply the sinoatrial node of the heart whereas those on the left side preferentially 
innervate the atrioventricular node [57]. 
The widespread influence of the vagus nerve and prominent role of the ANS in many disease 
states has made the vagus nerve a popular target for new research for a variety of indications. 
However, the complex anatomy presents challenges in clinical applications in fully understanding 
the intended and unintended effects of VNS therapy.   
 
2.5.2 Clinical Applications 
VNS has been clinically available for decades, but has been focused in neurological disorders. 
Left cervical VNS was first FDA approved to treat refractory epilepsy in 1997 and was later 
approved for use in treatment-resistant depression in 2005. In addition, several new indications 
have recently received FDA approval for the use of VNS therapy – morbid obesity (2015), cluster 
headaches (2017), and migraine headaches (2018). An example of the FDA-approved VNS system 
from LivaNova PLC is shown in Figure 2.11 (top panel). 
VNS continues to be investigated for numerous other conditions including HF, myocardial 
infarction (MI), diabetes, and chronic inflammation conditions. Here, we investigated the potential 
of VNS in treating HTN and HHD. This area of research has emerged only in the past several years 
and is quickly gaining interest leading to several clinical investigations. One clinical trial is 
currently underway at Massachusetts General Hospital where they are recruiting subjects for a 
study to investigate the effects of transcutaneous VNS (tVNS) in patients with HTN. The protocol 
consists of three stimulation sessions to evaluate the impact of tVNS on HR and BP metrics. An 
example of a transcutaneous VNS system from gammaCore is shown in Figure 2.11 (bottom panel).  
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Figure 2. 11 Examples of an invasive VNS system (LivaNova PLC; Figure adapted from 
http://www.livanova.com) and a noninvasive, transcutaneous VNS system (Gamma Core Inc.; 
Figure adapted from https://gammacore.com/). 
 
2.5.3 Experimental Findings 
The evaluation of VNS in treating HTN is still a new area of research with numerous preclinical 
studies being conducted to understand the beneficial effects of VNS therapy and its mechanisms of 
action. A majority of literature supporting the application of VNS in HTN has stemmed from 
investigations in other disease states including HF, MI, chronic inflammation, and atrial fibrillation 
(AF). The studies summarized here demonstrating numerous beneficial effects including BP 
control, autonomic control, cardiac remodeling, arrhythmia suppression, and a reduction in 
inflammation provide evidence supporting the investigation into the use of VNS for the treatment 
of HTN and HHD. 
 
2.5.3.1 Blood Pressure Control 
The most crucial element of an anti-hypertensive therapy is its ability to control the rise in BP 
and to help return BP levels back to normotensive values. VNS plays a key role in BP control 
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through its innervation to baroreceptors in the aortic arch. However, to date, limited studies have 
investigated the role of VNS in BP control in hypertensive [58-60] and healthy models [61-64]. 
Further, the majority of these findings are from acute applications of VNS while the animal was 
anesthetized, which may have confounding effects on VNS therapy. These studies in spontaneously 
hypertensive rats have shown an acute reduction in BP due to VNS [58, 59]. However, using this 
same HTN model in a chronic study, four weeks of VNS therapy did not alter the rise in systolic 
BP (SBP). Although BP was not affected, other beneficial effects were demonstrated such as 
improved endothelial function and the prevention of aortic stiffening [60].  
Acute studies in healthy rats have helped further the understanding of the parameter space and 
the mechanisms by which VNS can lower BP. Specifically, these studies have been developing 
more targeted VNS therapy to optimize this BP effect while limiting the occurrence of side effects 
such as bradycardia and bradypnea. Plachta et al. has evaluated the efficacy of isolating and 
stimulating the aortic depressor nerve (ADN) within the vagus nerve in healthy rats [62, 63]. The 
ADN is an afferent nerve that transmits signals from the receptors in the aortic arch to maintain 
homoeostasis [65]. Through selective ADN stimulation, BP is acutely lowered while avoiding 
significant changes in heart rate (HR) and respiration rate [62]. Further, this group evaluated the 
selective stimulation of the ADN while synchronized to the cardiac cycle to the mimic inherent, 
pulsatile activity of the ADN which proved improved therapeutic efficacy, which accounts for the 
intended effect, BP reduction, and the unintended effect, HR reduction [63].  
In general VNS has been shown to reduce BP, but discrepancies exist in scientific findings 
which can largely be due to parameter selection, selective versus nonselective stimulation, and 
disease model. Further acute and chronic studies are needed to HTN models to better understand 
the parameters space and optimize treatment for HTN and HHD. 
 
2.5.3.2 Autonomic Control 
Another critical aspect of VNS therapy is the impact on the ANS. Traditionally, clinical 
measures of heart rate variability (HRV) and baroreflex sensitivity (BRS) have been used as 
indicators of autonomic tone and carry strong prognostic value in CVD. HRV provides a measures 
of the sympathetic and parasympathetic influence in acute changes in HR while BRS evaluates the 
magnitude of the HR change in response to changes in BP. In the case of impaired autonomic 
balance, both HRV and BRS decrease, which is significantly associated with increased 
cardiovascular risk [66, 67].  
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The effect of VNS on these markers of autonomic tone have been evaluated in a normal 
physiological state [68] and in a state of altered autonomic balance present in HF [69, 70]. Zhou et 
al. evaluated the spectral components, specifically high frequency and low frequency components, 
of HRV in a healthy porcine model. Their results showed that acute application of VNS resulted in 
a decrease in the low frequency and increase in the high frequency components, demonstrating 
improved parasympathetic tone [68, 71]. A similar effect on low and high frequency components 
of HRV was demonstrated by Zhang et al. in a high-rate pacing HF canine model. Additional 
beneficial autonomic effects were observed in BRS measures which were preserved in the VNS-
treated group, with higher BRS values, measured at Weeks 4 and 8 of therapy, in comparison to 
the untreated group. 
The beneficial autonomic effect has also been demonstrated in humans with HF. A previous 
clinical trial, the ANTHEM-HF Trial, evaluated the efficacy of right- and left-sided VNS in treating 
HF patients. The ANTHEM-HF trial met their safety and efficacy endpoints and demonstrated an 
increase in HRV, evident in patients receiving both right- or left-sided VNS [72]. Further analysis 
on the dynamics of the autonomic HRV response was performed using Poincaré plots, which 
provides a visual representation of the variability in R-R intervals by plotting each R-R interval 
against the previous R-R interval [73].  Right-sided VNS resulted in increased SD1, representative 
of short term variability in R-R intervals, and a significant reduction in the centroid, representative 
of mean HR. This effect was highly correlated to the amplitude of the simulation. In contrast, the 
left-sided stimulation did not alter the Poincaré parameters unless stimulation was raised 
sufficiently high, greater than 2 mA [70]. This laterality was also demonstrated by Zhou et al. in 
which the spectral measures of HRV were only influenced by right- and not left-sided VNS [68]. 
These results suggest that a stronger cardiac autonomic effect can be achieved at lower stimulation 
thresholds through right-sided VNS, which preferentially innervates the sinoatrial node.  
 
2.5.3.3 Cardioprotection 
The vagus nerve has a strong influence on the heart through direct innervation to the atria and 
the ventricles. Parasympathetic activation has negative chronotropic, inotropic, and dromotropic 
effects [74]. These effects are well documented, and initially the drop in HR was thought to be a 
necessary component of the cardioprotective effect of VNS. However recent studies have shown 
beneficial cardiac effects without HR reduction [75]. Numerous studies have been conducted to 
evaluate the cardioprotective role of VNS in the atria and the ventricles separately and the role of 
therapy in arrhythmia suppression. 
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2.5.3.3.1 Atrial Remodeling and Arrhythmia Suppression 
A large body of research exists demonstrating the pro- and anti-arrhythmic effects of VNS. 
Traditionally, VNS has been used to induce AF in acute animal studies [76-78], and the ablation of 
the vagus nerve was shown to prevent or reduce the occurrence of AF in these models [77]. 
Specifically, the release of acetylcholine by stimulating the vagus nerve results in shortening of 
atrial action potential duration (APD) and effective refractory period (ERP) and an increase in 
spatial heterogeneity, due to the non-uniform distribution of vagal innervation in the atria. Taken 
together, these effects increase the atria’s susceptibility to arrhythmias and the probability of 
multiple reentrant circuits [79]  
However, recent research has shown VNS has cardioprotective and anti-arrhythmic properties 
in the atria. Ultimately, these antagonistic effects are a result of the intensity of the stimulation. An 
experiment in canines demonstrated the impact of stimulation intensity and revealed that high 
intensity stimulation, which slows the heart rate by 60% or more, facilitated AF, while moderate 
intensity stimulation, slowing the heart rate by no more than 40%, did not affect AF [76]. Animal 
studies have confirmed this anti-arrhythmic effect in several studies using low-level VNS [80-82]. 
Specifically, VNS was shown to inhibit intrinsic cardiac autonomic nervous activity in the major 
ganglionated plexi [82] as well as prevent atrial electrophysiological remodeling induced via rapid 
atrial pacing [81]. Additional studies have demonstrated this effect in humans [83-85] where acute 
VNS sessions have shown lasting effects in AF suppression [84, 85]. Further, some of the most 
compelling evidence demonstrating that VNS is not pro-arrhythmic, in its current clinical 
application, comes from the thousands of patients implanted with VNS who have not experienced 
an increase in the risk of developing AF [86-89]. 
 
2.5.3.3.2 Ventricular Remodeling and Arrhythmia Suppression  
Initially, due to the concentration of vagal fibers in the atria, the ventricles were thought to be 
unaffected by VNS. However, studies have recently revealed the extensive presence of sympathetic 
and parasympathetic innervation in the ventricles.  Research showing the beneficial ventricular 
effects has been mostly focused on HF and MI. However, mechanistic insights from HF and MI 
studies can help inform studies designed to treat HTN and HHD.   
Investigating the effects of VNS in ventricular myocardium has resulted in a large number of 
studies with relatively consistent results demonstrating cardioprotection, maintaining electrical 
stability and suppressing arrhythmias. Further, several literature reviews have been written 
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summarizing the results [90, 91]. Briefly, results have shown that the use of VNS in treating cardiac 
diseases has resulted in an increase in in ventricular ERP [92, 93], APD [94], and ventricular 
fibrillation (VF) threshold [95, 96], accompanied with a reduction in the spatial dispersion of 
ventricular refectory period, VF occurrence [95, 96], and the maximum slope of the restitution 
curve, Smax [92]. Studies have also consistently reported improvements in left ventricular function 
including improved left ventricular ejection fraction, increased left ventricular end-systolic volume, 
and protection against left ventricular hypertrophy [75]. In addition, this anti-arrhythmic effect has 
been shown to persist even after the cessation of therapy suggesting a remodeling or memory 
component of the myocardium as a result of VNS applied over time [97]. Overall, the effects of 
VNS have demonstrated improvements in structural and electrophysiological properties of the 
ventricles, providing evidence as an efficacious therapy for not only HF and MI, but also providing 
promise as a therapy for HTN-associated CVD.   
Overall, these studies have shown that VNS is able to provide beneficial structural and 
electrical cardiac remodeling to and prevent the progression of CVD. VNS has the ability to 
maintain or restore electrical stability in the atria and ventricles to provide protective effects and 
reduced arrhythmia susceptibility. There are numerous mechanisms which are postulated to result 
in the anti-arrhythmic effect observed with VNS therapy including HR reduction [98], the 
preservation of connexin 43 [98, 99], inhibition of the opening of mitochondrial permeability pore 
[100], inhibition of SNS [100], and nitric oxide-mediated effects on ventricular APD restitution 
[92, 93, 95, 101]. Further studies are needed to evaluate which therapeutic mechanisms play a key 
role in HTN and HHD and whether these effects can be optimized through VNS parameter 
selection. 
 
2.5.4 Inflammation 
Recent research has shed light on the role of inflammation in HTN, particularly on the impact 
of adaptive immunity in the development and progression of HTN [102]. Although the cause-and-
effect relationship between inflammation and HTN remains unclear, research in this field continues 
to grow. In general, inflammation is a protective response to injury. However, chronic inflammation 
can have deleterious effects. In fact, increased levels of pro-inflammatory cytokines have been 
demonstrated in HTN and CVD [103-105]. Several studies have also observed an increase in pro-
inflammatory cytokines in patients at risk for HTN and CVD [106]. These results suggest that the 
systemic inflammation may precede the clinical diagnosis. One current hypothesis is that 
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inflammation can lead to endothelial dysfunction and increased oxidative stress, which promote 
the development and progression of HTN  (Figure 2.12) [107]. 
 
 
 
Figure 2.12 Schematic showing the role of inflammation in the pathogenesis of HTN. Adapted 
from Dinh et al. 2014 [107]. 
 
One of the major recent discoveries in VNS therapy is its profound impact on inflammation. 
VNS has the capability to reduce systemic inflammation through the activation of the cholinergic 
anti-inflammatory pathway, reducing cytokine synthesis and the inflammatory response [69, 108]. 
Animal studies in HF models have shown a reduction in pro-inflammatory cytokines as a result of 
VNS therapy [75, 109]. Specifically, Zhang et al. demonstrated a reduction in C-reactive protein 
(CRP) in VNS-treated HF canines [110]. Although this experiment was performed in a HF model, 
elevated CRP is strongly associated with HTN [105, 106]. Additional studies have observed 
decreases in inflammatory biomarkers of HF including TNF-α, IL-2, Il-6 and IL-18. Experimental 
evidence suggests that VNS may be able to help treat CVD through a reduction in inflammation 
[111, 112]. As a therapy for HTN, VNS has to potential to modulate the innate inflammatory 
response and reduce vascular end organ damage through decreased oxidative stress and subsequent 
endothelial dysfunction. More work in this area is needed to fully understand the role of these 
cytokines in the development of CVD and HTN, as they are unlikely to be “innocent bystanders” 
[113].  
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Numerous other mechanisms of VNS therapy, including  anti-adrenergic effect and inhibition 
of the renin-angiotensin system, have been evaluated in HTN and CVD models which could 
provide further understanding of the beneficial effects of VNS. Suppressing central sympathetic 
outflow through activation of vagal nerve afferent fibers can lead to a reduction in sympathetic 
nervous system activity, resulting in reductions in HR, vascular resistance, and arterial BP. VNS 
has also been shown to directly activate the nitric oxide pathway producing nitric oxide in the 
ventricles, altering cardiac electrophysiology and decreasing arrhythmia susceptibility [101]. 
Another proposed mechanism of VNS is inhibition of the renin-angiotensin system through afferent 
vagal nerves, resulting in a reduction in renin in the kidneys and marked reduction in plasm 
angiotensin II levels [69, 114].  
 
2.6 CONCLUSION 
VNS has demonstrated its ability to modulate key components in the pathogenesis of HTN. 
These results, taken together, show potential for VNS to treat HTN and associated cardiovascular 
risk through a combination of afferent and efferent parasympathetic activation. VNS has 
demonstrated strong beneficial cardiac effects, improving outcomes through electrical and 
structural remodeling, as well as BP control, specifically demonstrated through direct activation of 
the afferent ADN. In addition this new therapeutic approach could be leveraged to overcome 
current treatment limitations, such as treatment resistance and noncompliance, and help achieve 
improved patient outcomes.  
Although numerous studies have been completed investigating VNS as a novel therapy having 
strong beneficial effects on the heart, autonomic balance, and inflammation, limited research is 
available on the potential of VNS to treat HTN and associated cardiovascular remodeling. Chronic 
studies are necessary to evaluate the full potential of VNS therapy in HTN and HHD, specifically 
evaluating long-term survival, hemodynamic and cardiovascular responses, and the associated 
cardiac electrical and structural remodeling. In this work, I evaluate these effects of chronic low-
level VNS applied to the right cervical vagus nerve in DSS hypertensive rats.  
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Chapter 3 
 
Intermittent electrical stimulation of the right cervical vagus 
nerve in salt-sensitive hypertensive rats: effects on blood 
pressure, arrhythmias and ventricular electrophysiology 
 
3.1 INTRODUCTION 
Chapter 3 presents the methods and findings from the first chronic study of vagus nerve 
stimulation (VNS) therapy in a Dahl salt-sensitive (DSS) hypertensive rat model. The main 
objective was to evaluate the efficacy of chronic VNS therapy in hypertension (HTN) using in-vivo 
and ex-vivo analysis techniques. The progression of HTN is quantified over time using in-vivo 
physiological recorders to get real-time blood pressure (BP) and ECG recordings. Ex-vivo studies 
using optical mapping were performed to evaluate the impact of VNS therapy on the 
electrophysiological properties of the hypertensive heart.  
HTN is one of the strongest risk factors for sudden cardiac death [115]. Over time, HTN leads 
to left atrial dilation, left ventricular hypertrophy, and impaired ventricular relaxation (i.e., 
“diastolic dysfunction”), and thus, affecting ventricular systole, diastolic filling, and increasing the 
risk of heart failure (HF) [116]. In addition to adverse structural changes in the myocardium, 
chronically elevated BP also negatively affects autonomic regulation of BP [117], heart period 
dynamics [118], and electrophysiological properties of neural and myocardial tissues of the heart, 
causing progressive symptom expression and elicitation of spontaneous cardiac arrhythmias. The 
presence and the complexities of these cardiac arrhythmias in hypertensive patients significantly 
influence the morbidity, mortality, and quality of life [119-122].  
Currently, the most common treatment option prescribed by physicians for patients with HTN 
and HTN-induced heart diseases (HHD) is a regimen of antihypertensive drugs along with diet and 
exercise. However, there are still numerous limitations with this approach and nearly half of all 
hypertensive patients do not achieve controlled BP levels. As a result, there is a clear need for novel 
and effective alternative treatments for HTN and HHD. 
VNS has the capability of restoring autonomic nervous system (ANS) regulatory function not 
only in the vascular system but also in the heart at its neural processing hierarchy [123]. Our 
laboratory and others have shown that VNS is able to alter several electrophysiological properties 
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of the heart, eventually suppressing arrhythmias and leading to an improved prognosis of HF rats, 
and significantly improved long-term survival after chronic HF [124, 125].  
 
3.2 AIM 
In the present study, we investigated for the first time the potential of VNS to be used as a 
novel device-based therapy for HTN and HHD. Specifically, this study aimed to determine the 
effects of VNS on the evolution of mean arterial pressure (MAP) and arrhythmogenesis in-vivo in 
a genetic model of HTN, the DSS rat. In addition, at the end of the study, the effect of VNS therapy 
on the electrophysiological properties of the heart were evaluated through ex-vivo optical mapping. 
 
3.3 METHODS 
All procedures were approved by the University of Minnesota Animal Care and Use Committee 
and were conducted in accordance with institutional and NIH guidelines.  
Prophylactic antibiotic (gentamicin sulfate; 10 mg/kg, i.m.) was given prior to each surgery. 
During the surgeries, rats were anesthetized with isoflurane (5% for induction, 2% or 3% for 
maintenance) in oxygen (2 L/min for induction and 1L/min for maintenance). The rat’s body 
temperature was maintained at 37°C on a temperature-controlled surgery table.  
 
3.3.1 Experimental Design 
DSS male rats (n = 12, 5 weeks old) were used for the study. HTN was induced via 8% NaCl 
high salt diet (S10001, Research Diets, Inc., NJ, USA) and was maintained throughout the entire 
duration of the study (Figure 3.1A). Vagus nerve stimulators (Cyberonics Model 103, Houston, 
TX, USA) and telemetry systems (HD-S11, Data Sciences, Inc. (DSI), Minneapolis, MN, USA) 
were implanted at Week 5 of the study, and the rats were randomly divided into two groups: Sham 
(n = 6, with nonfunctional VNS stimulator implants of the same mass) and VNS (n = 6, with 
functional VNS stimulator implants). At the end of Week 6 (Figure 3.1A, “Day 0 VNS”), functional 
stimulators were activated in the VNS group, and real-time bipolar electrograms and arterial BP 
were recorded using DSI telemetry for both VNS and Sham groups for 4 weeks (Week 6 through 
Week 10).  
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Figure 3.1 A) Experimental design timeline. HTN was induced through 6 weeks of high salt diet 
(8% NaCl). DSI transmitters and VNS devices were implanted during Week 5. Rats were randomly 
divided into 2 groups: Sham (n=6) with non-functional VNS stimulators and VNS (n=6) with 
functional stimulators. VNS therapy was turned on at Week 6, and ECG and blood pressure were 
monitored in both groups. B) Sample ECG (top) and arterial blood pressure (bottom) recordings 
from DSI telemetric devices. Insert: MAP is calculated using SBP and DBP measured from the 
blood pressure recordings. 
 
3.3.2 Vagus Nerve Stimulator Implantation 
The VNS pulse generator and lead were implanted as described previously [125, 126]. The 
back and the neck of the rats were shaved, and the right cervical vagus nerve and common carotid 
artery bundle were isolated from the surrounding tissue through a small incision on the neck. 
Bipolar cuff electrodes were placed around the bundle. The pulse generator (8cc, 14g) was 
implanted subcutaneously and positioned on the back of the rat. Parameters of the intermittent VNS 
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were set as follows: pulse frequency 20 Hz; pulse width 500 μsec, output current 1.0 mA. The pulse 
generator was programmed using radio-frequency telemetry to deliver continuously cyclic VNS: 7 
seconds “On” and 66 seconds “Off”. With a two-second ramp up and ramp down period before and 
after the stimulation on time, the duty cycle of the VNS therapy applied was 15%. Nonfunctional 
stimulators were implanted in the Sham rats to provide the same mass (14 g).  
 
3.3.3 DSI Telemetry System Implantation 
The DSI transmitter implantation was performed as described previously [127]. Briefly, the 
surgical regions (chest and inner leg) were shaved and the transmitter pressure catheter was 
implanted into the descending aorta via the left femoral artery through a small incision in the 
inguinal area. The two ECG leads were fixed subdermally on the chest muscle. Following recovery 
from surgery, rats were conscious and freely moving in their home cages for the duration of the in-
vivo study. Continuous arterial BP and ECG data acquisition were performed with the use of a 
commercially available telemetry system (DSI, Inc.). The real-time bipolar electrograms and 
arterial BP data were collected with a 500 Hz sampling rate. Each cage was placed on a receiver 
(model RPC1, DSI Inc.) that was connected to a computer via a Data Exchange Matrix (DSI Inc.). 
 
3.3.4 Optical Mapping 
Upon completion of the in-vivo protocol (Figure 3.1A), rats were sacrificed for heart extraction 
through thoracotomy. The hearts were immersed in cold cardioplegic solution and Langendorff-
perfused with warm (37 +/- 1°C) oxygenated Tyrode’s solution as described in detail previously 
[128]. After 30 minutes of stabilization, the voltage sensitive dye di-4-ANEPPS (5 ug/mL) was 
added to the perfusate. Two 532 nm green lasers (Millenia Pro 5su, Spectra-Physics Inc., Mountain 
View, CA, USA) were used to illuminate both the right (RV) and left ventricles (LV) of the heart, 
and the fluorescence signal from more than 80% of the total ventricular surface was captured with 
two 14-bit CCD cameras (Little Joe CCD39, SciMeasure Analytical Systems, Inc., GA, USA), that 
ran synchronously at 1000 frames per second with 80 x 80 pixel resolution (the field of view was 
12 x 12 mm). Blebbistatin (10-15 uM) was added to stop heart contractions and reduce motion 
artifacts.  
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3.3.5 Gross Morphology 
Tibia length (TL)-normalized heart weight (HW) was used to quantify the effect of VNS on 
the cardiac structure to avoid the confounding effects of body weight. The left leg of the rat was 
severed above the knee joint, and the muscle and skin of the tibia were removed by mechanical 
stripping. The length of the tibia from the condyles to the tip of the medial malleolus was measured 
using micrometer caliper. HW normalized by TL (HW/TL) was compared between Sham and VNS 
rats at the end of the study. The RV and LV free-wall thickness was measured after optical mapping 
experiments to obtain an RV/LV wall thickness to quantify hypertrophy in the HTN hearts.  
 
3.3.6 Data Analysis 
3.3.6.1 In-Vivo DSI Telemetry System Data Analysis 
Representative examples of simultaneously recorded ECG and arterial BP traces obtained from 
the DSI telemetry system are shown in Figure 3.1B during VNS “On” and “Off” periods. Note the 
presence of small artifacts on the ECG traces (arrows) while VNS therapy is applied (Figure 3.1B, 
top panel).  
The ECG traces were used for the estimation of arrhythmia episodes using commercial 
software (Ponemah Life Science Suite, DSI Inc., MN, USA). Episodes of arrhythmias were counted 
one day prior to the start of therapy (“Day 0 VNS”) and at the end of the study (Week 10) during 
the same time interval (four hours at night), and were presented as the number of episodes per hour 
per rat. Several types of arrhythmic events were observed: premature ventricular complexes (PVC), 
atrial fibrillation (AF), bradycardia, and skipping beats. PVC episodes were separated from all other 
arrhythmic events, as PVCs can occur in a healthy rat and poses less of a threat to the heart than 
the other types of arrhythmias.  
From the arterial BP traces, the following parameters were calculated using commercial 
software (Dataquest A.R.T., DSI Inc., MN, USA): heart rate (HR), heart rate variability (HRV), 
systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), and MAP, as 
indicated in Figure 1B. ΔHR was also calculated to determine the relative changes in HR over the 
duration of VNS therapy. ΔHR was defined as 
Δ𝐻𝑅 = (𝐻𝑅𝑛 − 𝐻𝑅0), 
Where 𝐻𝑅𝑛is the HR at day n after VNS activation, and 𝐻𝑅0 is the HR measured at “Day 0 VNS.” 
The relative changes in MAP were calculated as 
ΔMAP = (𝑀𝐴𝑃𝑛 − 𝑀𝐴𝑃0), 
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Where 𝑀𝐴𝑃𝑛is the MAP at day n after VNS activation, and 𝑀𝐴𝑃0 is the MAP measured at “Day 0 
VNS” (See Figure 1A). The values for ΔMAP and ΔHR were calculated separately for the 12-hour 
day (7am – 7pm) and night (7pm-7am) time intervals.  
 
3.3.6.2 Ex-Vivo Optical Mapping Data Analysis 
Optical action potential durations (APD) were measured at 80% repolarization (APD80), and 
two-dimensional (2D) APD maps were constructed to reveal the spatial distribution of APDs on 
both the LV and RV epicardial surfaces. Mean APD was calculated at different basic cycle lengths 
(BCLs) for the visible RV and LV surfaces by averaging APDs from all pixels. The maximum 
slope of the APD restitution, Smax, was calculated at the smallest diastolic interval. 2D maps of Smax 
were constructed to evaluate its spatial distribution and calculate the mean value of Smax on the 
epicardial surface.  
The spatial dispersion of APD was estimated based on the heterogeneity index 
𝜇 =
𝐴𝑃𝐷95 − 𝐴𝑃𝐷5
𝐴𝑃𝐷50
 
where APD95 and APD5 represent the 95th and 5th percentiles of the APD distribution, respectively, 
and APD50 is the median APD distribution.  
To measure the local conduction velocity (CV), the distributions of the activation times (AT) 
over a spatial region of 5 x 5 pixels were fitted with a plane, and the gradients of ATs gx and gy 
were calculated for each plane along the x and y axes, respectively [128]. The magnitude of the 
local CV was calculated for each pixel as 
(𝑔𝑥
2 + 𝑔𝑦
2)−
1
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During sustained ventricular tachycardia (VT) or VF, optical movies were acquired for 10 
seconds, and the first 3000 frames (3 seconds) of each episode were used for VT/VF analysis. For 
each VT/VF episode, fast Fourier transform was applied at each pixel to obtain the power spectrum 
and determine the distribution of frequencies in the range of 5-35 Hz. The dominant frequency 
(DF) was defined as the frequency corresponding to the highest peak in the power spectrum [128]. 
2D DF maps were constructed and used to determine the maximum DF (DFmax) on the epicardial 
surface, as well as the number of DF domains. The minimum size of the domain was considered to 
be 100 pixels with resolution of 0.01 Hz between domains.  
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3.3.7 Statistics 
Data are presented as mean +/- standard error. Statistical comparisons between Sham and VNS 
rats were performed using one-way ANOVA. P < 0.05 was considered to be statistically significant.  
 
3.4  RESULTS 
3.4.1 In-Vivo Effect of VNS on Blood Pressure, ECG, and Arrhythmias in HTN Rats 
Table 3.1 shows in-vivo BP and ECG twenty four-hour mean parameters (MAP, PP, HR, and 
HRV) at Weeks 5, 6, 8, and 10 for all Sham and VNS rats. Table 1 indicates that 6 weeks of high 
salt diet successfully induced HTN in both Sham and VNS groups, as indicated by a significant 
increase in MAP and PP, as well as a significant decrease in HR. Note that there were no significant 
differences between the groups in any parameter at either baseline or Week 6.  
 
Table 3.1 In-vivo blood pressure and ECG parameters for Sham and VNS rats 
  Week 5 
(Baseline) 
Week 6:  
Day 0 VNS 
(8% NaCl) 
Week 8 
(8% NaCl 
+VNS) 
Week 10 
(8% NaCl 
+VNS) 
HR 
(BPM) 
VNS 436 ± 10 *408 ± 10 421 ± 9 *407 ± 3 
Sham 442 ± 10 *399 ± 7 *
#
380 ± 12 *397 ± 9 
MAP 
(mmHg) 
VNS 120 ± 3.5 *157 ± 6.0 *
†
171 ± 10.4 *
†
179 ± 11.6 
Sham 112 ± 2.5 *155 ± 11.7 *
†
174 ± 10.0 *
†
200 ± 15.7 
PP 
(mmHg) 
VNS 47 ± 2.8 *56 ± 2.7 *
†
62 ± 3.0 *60 ± 1.6 
Sham 38 ± 5.7 *59 ± 3.4 *58 ± 4.0 *61 ± 3.0 
HRV 
VNS 0.091 ± 0.009 0.090 ± 0.007 0.097 ± 0.012 0.108 ± 0.021 
Sham 0.099 ± 0.006 0.097 ± 0.009 *
†
0.119 ± 0.004 0.099 ± 0.015 
* denotes significance with respect to Week 5 (p < 0.05) 
† denotes significance with respect to Week 6 (p < 0.05) 
# denotes significance between Sham and VNS groups (p < 0.05) 
 
Figure 3.2 shows relative changes of twenty four-hour mean data for MAP (A), PP (B), and 
HR (C) with respect to baseline (Week 5) for both Sham and VNS groups. The data are shown at 
different times during VNS stimulation: Week 6 (“Day 0 VNS”), Weeks 8 and 10 (after 2 and 4 
weeks of VNS, respectively). Figure 3.2 shows that further development of HTN (Weeks 8 and 10 
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in comparison to Week 6) did not affect relative change in HR and PP, but significantly increased 
MAP in the Sham but not the VNS group. Note that the relative changes in HR and PP are larger 
in the Sham group in comparison to the VNS group, although statistical significance is only present 
at some weeks.  
 
Figure 3.2 Relative change of 24-hour mean data for A) MAP; B) PP; and C) HR with respect to 
baseline data (Week 5) for both Sham and VNS rats. † indicates statistical significance (P < 0.05) 
with respect to Week 6; # indicates statistical significance (P < 0.05) between VNS and Sham. 
 
To further investigate the effect of VNS on MAP and HR, we calculated ΔMAP and ΔHR, 
which reflect relative change in MAP and HR at each day with respect to “Day 0 VNS.” Figure 3.3 
shows the change in ΔMAP (Panels A and B) and ΔHR (Panels C and D) for the entire duration of 
VNS stimulation separately for the day and night time periods, as rats were housed in rooms that 
have automatic controlled light-dark cycles. Figure 3.3A shows the long-term VNS treatment 
attenuated the increase in ΔMAP during the day time interval, where parasympathetic system is 
playing the dominant role in rats. This effect becomes statistically significant toward the end of the 
study (P < 0.05, # in Figure 3.3A). On the other hand, VNS has no significant effect on ΔMAP 
during the night time interval, where sympathetic activity is dominant. Figure 3.3 panel C and D 
indicate that the ΔHR in both Sham and VNS groups has similar trend over time suggesting no 
chronic effect of VNS on HR, which is expected since the duty cycle of the VNS treatment was 
only 15%.  
Lastly, this study investigated the effects of VNS on the development of arrhythmias that are 
induced in the rats as a result of HTN. Figure 3.4A shows simultaneous recordings of arterial BP 
and ECG from an implantable DSI transmitter for Sham rats, demonstrating examples of a PVC 
(left) and a skipped beat (right). Similar types of abnormal cardiac behaviors were observed in VNS 
rats. However, there were a smaller number of occurrences of these arrhythmias in the VNS rats 
compared to the Sham rats. Figure 3.4B shows the total numbers of PVCs and arrhythmia episodes 
counted in both groups at Week 6 (“Day 0 VNS”) and Week 10. Note the reduction in both PVCs 
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and other arrhythmic episodes (P < 0.05) in VNS rats, indicating the antiarrhythmic effects of VNS 
therapy in HTN rats.   
 
 
Figure 3.3 A, B) ∆MAP and C, D) ∆HR during the day (7am-7pm) (panels A and C) and night 
(7pm-7am) (panels B and D) for the Sham and VNS rats. # indicates statistical significance (P < 
0.05) between VNS and Sham. 
 
Figure 3.4 A) Examples of episodes of a PVC (left) and other arrhythmias (skipped beats, right) 
from Sham rat at Week 6. B) Mean number of episodes of PVCs and other arrhythmias between 
Week 6 and Week 10 for Sham and VNS rats. † indicates statistical significance (P < 0.05) between 
Week 6 and Week 10. 
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3.4.2 Ex-Vivo Effect on VNS on Electrophysiological Properties of the HTN Hearts 
Typical examples of 2D APD maps of the RV and LV of Sham and VNS rat hearts obtained at 
a BCL of 200 ms are presented in Figure 3.5A. Corresponding traces of action potentials from a 
representative single pixels are shown in Figure 3.5B. Mean APD80 calculated in both groups for 
various BCLs are presented in Figure 3.5C for RV (left panel) and LV (right panel). Note that VNS 
reduced APD in the RV, with significant reduction at BCLs 120, 140, and 160 ms, but not in the 
LV. In addition, the maximum slope of APD restitution curve (Smax) was significantly reduced in 
the RV but not in the LV as a result of VNS therapy, as indicated in Figure 3.5D. 
 
 
Figure 3.5 A) Representative examples of 2D APD80 maps calculated at BCL=200 ms for RV and 
LV of VNS and Sham hearts. B) Single pixel action potential traces taken from the RV (●) and LV 
(■) data from panel A for VNS (solid line) and Sham (dashed line) hearts. C) Mean APD80 as a 
function of BCL for the RV and LV of VNS (n=5) and Sham (n=5) hearts. D) Mean Smax values 
for the RV and LV of all VNS and Sham hearts. # indicates statistical significance (P < 0.05) 
between VNS and Sham. 
 
To determine whether VNS affected the spatial dispersion of APD, we calculated the 
heterogeneity index, 𝜇, separately for the RV and LV at different BCL values. Figure 3.6A indicates 
that VNS significantly reduced μ in the LV but not in the RV at most BCLs.  
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To study whether VNS affected CV of action potential propagation, AT maps were constructed 
for both Sham and VNS groups at various BCLs. A representative example of AT maps at a BCL 
of 180 ms is shown in Figure 3.6B, indicating normal propagation in the RV of both the Sham and 
VNS rat hearts. Figure 3.6C shows mean CV data at different BCLs for both groups indicating that 
VNS increased CV both in the RV and LV, although the effect is significant only at some BCLs.  
 
 
Figure 3.6 A) APD heterogeneity index, µ, and C) mean CV as a function of BCL for the RV and 
LV of VNS and Sham hearts. B) Representative examples of activation time maps calculated at 
BCL=180ms. # indicates statistical significance (P < 0.05) between VNS and Sham. 
 
To investigate the effect of VNS on dynamical behavior of ex-vivo arrhythmias, optical 
mapping videos were analyzed from either spontaneously arrhythmias or from those induced at the 
end of the pacing protocol. In the optical mapping experiments, sustained VF was observed in all 
(6/6) Sham rats, while sustained VT, but not VF, was observed in four out of six VNS rat. None of 
the VNS rats developed VF, suggesting that VNS provided protection against the development of 
VF. The analysis of VT/VF dynamics is shown in Figure 3.7 panel A and B. Figure 3.7A shows a 
representative example of 2D DF maps for the RV of VNS and Sham rat hearts (top) with the single 
pixel traces (bottom) clearly indicating the presence of VT/VF. The DFmax and number of DF 
domains in the Sham and VNS rats are shown in Figure 3.7B. Note that the Sham rats not only had 
more DF domains but also had higher DFmax values than the VNS rats, indicating more complex 
dynamics of ex-vivo cardiac arrhythmias. Representative examples of phase movies during 
arrhythmias in VNS and Sham hearts are shown in Figure 3.7B. 
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Figure 3.7 Dynamics of ex-vivo arrhythmias. A) Representative examples of 2D DF maps from the 
RV of VNS and Sham hearts (top) and single pixel sample traces of VT (●) and VF (■) (bottom). 
B) Maximum DF as a function of number of frequency domains from all arrhythmic episodes in 
VNS and Sham hearts. # indicates statistical significance (P < 0.05) between VNS and Sham. C) 
Snapshot of representative examples of phase movies during arrhythmias for VNS and Sham hearts. 
 
Lastly, the HW/TL and the RV/LV wall thickness ratios were calculated at the end of the study. 
The results demonstrate that both parameters were similar in the VNS (HW/TL: 0.38 +/- 0.03; 
RV/LV: 0.32 +/- 0.01) and Sham (HW/TL: 0.42 +/- 0.01; RV/LV: 0.30 +/- 0.01, P = N/S) rats 
suggesting that four weeks of VNS therapy did not induce structural remodeling of the HTN hearts.  
 
3.5  DISCUSSION 
Autonomic dysregulation is a feature of chronic HF and is characterized by a sustained 
abnormal elevation in sympathetic nerve activity and a withdrawal of parasympathetic nerve 
activity [129-131]. Autonomic imbalance, which is reflected in reduced HRV and reduced 
baroreflex sensitivity, is associated with worsening HF and increased risk of mortality [132, 133]. 
Modulation of parasympathetic activation with electrical stimulation is a potential therapy for HF, 
but has received limited attention due to its inherent complex cardiovascular effects [134-136]. 
However, recent clinical studies have demonstrated the salutary effects of parasympathetic 
stimulation in HF [72, 137].  
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In the present study, for the first, a hypertensive rat model was used to characterize the effect 
of VNS on BP and arrhythmia incidence, as well as the effects of VNS on the electrophysiological 
properties of the heart. The results confirm that VNS therapy modulates the balance of the ANS 
whether by promoting parasympathetic activity, decreasing sympathetic activity, or a combination 
of the two.  
The major findings of this study are as follows: (1) 4 weeks of intermittent VNS attenuated the 
increase in MAP in VNS rats compared to Sham rats; (2) VNS reduced the number of in-vivo 
arrhythmic events, as well as the spatiotemporal complexity of ex-vivo arrhythmias in VNS rats 
compared to Sham rats; (3) VNS induced beneficial changes in the electrophysiological properties 
of the heart, including a reduction in APD during rapid drive pacing, 𝜇, and Smax, and an increase 
in CV. Overall, these results provide further evidence for the therapeutic efficacy of VNS in HTN 
and HHD.  
 
3.5.1 The Effect of VNS on Blood Pressure 
Recent studies have shown that chronic electrical stimulation of the carotid sinus activates the 
baroreflex and reduces MAP by inhibiting central sympathetic outflow [138, 139]. This reduction 
of BP is substantial, and is currently being used as a clinical therapy for resistant HTN [140, 141].  
The present study shows that chronic VNS also causes an attenuation of MAP elevation during 
the spontaneous development of chronic HTN, likely through similar mechanisms. In this study, 
the light-dark cycle for the rats has been accounted for. The rationale for the day-night separation 
is that the roles of the sympathetic and parasympathetic nervous system are different when the rats 
are active (during the night) and at rest (during the day). At rest, parasympathetic activity 
predominates over sympathetic tone [142]. Recently, it was demonstrated that the sympathetic and 
parasympathetic nervous systems are involved in diurnal variation in heart rate-corrected QT-
intervals (QTc) in rats [143]. Specifically, the enhanced parasympathetic nervous activity during 
the night induces a slight but significant QTc prolongation. Our results show that VNS induced a 
more pronounced modulation of MAP during the daytime, when the rats are less active and 
sleeping, and suggest that VNS is more effective when parasympathetic nerve activity 
predominates and the sympathetic tone is reduced. This is an indirect indication that the 
parasympathetic nerve activity is impaired by HTN; and that VNS lowers MAP by enhancing 
parasympathetic nerve activity and restoring autonomic balance.  
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3.5.2 The Antiarrhythmic Effects of VNS 
The antiarrhythmic effects of VNS in ischemic HF are shown in previous studies [144-146]. In 
this study, the results demonstrate that VNS also has antiarrhythmic effects in HHD. VNS therapy 
significantly reduced the incidence of in-vivo arrhythmias (tachycardia, bradycardia, and skipped 
beats) in hypertensive rats. In addition, the optical mapping results demonstrated that the 
complexity of the spontaneous and induced ex-vivo arrhythmias is significantly reduced in VNS 
rats compared to Sham rats, which is further evidence of the antiarrhythmic effects of VNS 
treatment in HHD.  
Antiarrhythmic effects were associated with significant VNS-induced reduction in the APD 
and the slope of APD restitution in the RV, as well as the reduction in the spatial dispersion of APD 
and increase in CV in the LV during rapid drive pacing. The electrophysiological changes that 
occurred due to VNS in the LV are in contrast to those that were observed in most HF hearts. 
Reduction in CV and increase in 𝜇 have been shown to create an arrhythmic substrate that is able 
to promote the inception and preservation of reentrant arrhythmias [147, 148]. In HF, conduction 
slowing has been linked to a decrease in expression of gap-junction protein Connexin-43 [149]. 
Likewise, elevated Connexin-43 expression is correlated with faster conduction in the myocardium 
[150]. Short-term VNS therapy has been previously shown to preserve the expression of gap-
junctional protein Connexin-43 over the course of minutes after cardiac injury [98]. Although, in 
this study, Connexin-43 expression in the LV was not directly measured, the results seem to agree 
with this finding. All of these electrophysiological changes are likely contributing to the 
antiarrhythmic effects of VNS.  
The exact mechanisms underlying the antiarrhythmic effects of VNS are still not well 
understood. One possible mechanism may be due to the activation of the vagus nitric oxide (NO) 
pathway, since direct neural stimulation of the vagus nerve releases NO through a neuronal NO 
synthase mechanism in the ventricle. Brack et al. previously demonstrated the important role of 
NO in mediating the protective effects of VNS in the rabbit hearts [95, 101]. Another possible 
mechanisms may involve reactive oxygen species (ROS). It is known that during myocardial injury, 
there is an increase in ROS production and oscillation of the mitochondrial membrane potential, 
which plays an important role in the genesis of cardiac arrhythmias [151]. Shinlapawittayatorn et 
al. has demonstrated that VNS was able to stabilize cardiac mitochondrial membrane potential by 
protecting the depolarization of the mitochondrial membrane [126]. 
It is important to note that in this study, only a limited number of spontaneous arrhythmic 
episodes were evaluated, and therefore, arrhythmias were relatively scarce even in Sham rats. 
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Another approach, such as stressing the heart using programmed stimulation, might have led to 
stronger results.  
 
3.5.3 Mechanistic Insights into Chronic VNS Therapy 
At the cervical level, the vagus nerve contains a composite of myelinated A- and  B-fibers, as 
well as unmyelinated C-fibers, which are the most numerous (approximately 65% to 80%) [152]. 
According to Woodbury et al. [153], activation of C-fibers requires higher stimulation amplitudes 
and longer pulse durations compared to the activation of the myelinated A- and B-fibers. For 
instance, Zagon et al. demonstrated that the myelinated vagal fibers were activated in anesthetized 
rats at 100 μA (at 30 Hz and a pulse width of 0.5 ms), while increasing current up to 200 μA 
activated the nonmylinated fibers [154]. The stimulation parameters that have been used in this 
study (pulse width of 0.5 ms and current of 1.0 mA) suggest that both myelinated and unmyelinated 
fibers are stimulated. Similar levels of stimulation will also engage the vagal motor fibers, 
especially the myelinated fibers, according to the study of Ben-Menatchem et al. [155]. Future 
studies are needed to determine whether the therapeutic mechanism of VNS predominately occurs 
through afferent or efferent neural pathways. 
In addition, chronic VNS may also provide an anti-inflammatory effect through the cholinergic 
anti-inflammatory pathway. The neural signal that is sent from the efferent fibers in the vagus nerve 
can inhibit the release of cytokines and release the neurotransmitter acetylcholine. Cytokine-
producing cells contains acetylcholine receptors which transduce signals resulting in the inhibition 
of cytokine synthesis. By decreasing the level of cytokine synthesis, the magnitude of the 
inflammatory response is dampened [108]. This effect was demonstrated by Zhang et al. by 
measuring the plasma C-reactive protein (CRP) levels [110]. Pacing-induced HF promotes 
systemic inflammation and was shown to have increased plasm CRP. VNS treatment significantly 
reduced the plasm CRP.   
 
3.6 CONCLUSION 
The results of this study clearly demonstrate that VNS is capable of attenuating the high MAP 
in the hypertensive rats and inducing antiarrhythmic effects, which provides evidence for VNS as 
an effective device-based therapy for HTN and HHD. The results also suggest that the therapeutic 
effects of VNS are associated with chronic treatment, rather than acute stimulation. Indeed, the 
beneficial effect of VNS on attenuating high MAP became significant only after four weeks of 
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chronic VNS therapy. Therefore, further evaluation of VNS as a clinical HTN therapy requires 
prolonged chronic stimulation.  
This study demonstrates the beneficial effects of VNS on blood pressure and arrhythmias in a 
hypertensive rat model and investigates the effect of VNS on several electrophysiological 
parameters. Nevertheless, more comprehensive evaluation is required to reveal the mechanisms by 
which VNS affects different in-vivo and ex-vivo electrophysiological and structural characteristics 
of the rats. The current study raises a number of questions that can help in designing future 
experiments.  
The results show that VNS affected the RV and LV in slightly different ways. Indeed, VNS 
reduced APD and Smax only in the RV, but increased CV and decreased APD spatial dispersion 
predominately in the LV. This suggests that different electrical remodeling of both ventricles takes 
place as a result of chronic HTN and VNS therapy. On the other hand, the data does not suggest 
any anatomical remodeling of either ventricles. These results are somewhat intriguing since the LV 
(but not the RV) contractile properties are expected to be the main determinant of MAP. It is unclear 
whether the RV/LV electrophysiological remodeling is accompanied by a remodeling of the 
corresponding extracellular matrix. 
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Chapter 4 
 
Chronic low-level vagus nerve stimulation improves long-term 
survival in salt-sensitive hypertensive rats 
 
4.1 INTRODUCTION 
Chapter 4 presents the methods and results for a chronic survival study to evaluate the long-
term efficacy of vagus nerve stimulation (VNS) as a therapy in a dahl salt-sensitive (DSS) 
hypertensive rat model. Methods for longitudinal data analyses of the cardiovascular, 
hemodynamics, and autonomic responses are presented and used to evaluate the progression of 
hypertension (HTN) and the role of VNS therapy. Ex-vivo studies are also described as a means to 
investigate the impact of VNS therapy on cardiac structural properties. 
HTN most prominent risk factor for cardiovascular disease (CVD) [1, 156], and cardiovascular 
complications due to HTN result in over 9 million deaths annually [157]. The need to control the 
rise in blood pressure (BP) while also addressing the negative effects of complex co-morbidities 
makes the clinical management of HTN challenging. Currently, the majority of hypertensive 
patients are treated with antihypertensive drugs to control BP. However, many limitations exist, 
including resistant HTN, inability to tolerate therapy, and non-compliance with the medication 
regime [122, 158]. There is a need for novel treatment options for hypertensive patients to control 
BP while also addressing the adverse cardiac effects of HTN.  
Recently, we proposed to specifically target the parasympathetic nervous system using VNS, 
and evaluated the efficacy of four weeks of VNS treatment for HTN and HTN-induced heart disease 
(HHD) in a rat model of HTN [159].  Our study and others have demonstrated the beneficial effects 
of chronic VNS in treating HTN, and its associated improvement of endothelial function and 
cardiac electrophysiological properties, leading to suppression of ventricular arrhythmias [60, 92, 
125]. Antiarrhythmic effects have also been recently demonstrated by our lab in healthy hearts in 
the absence of sympathetic overdrive [160]. Further, acute VNS therapy has also shown a beneficial 
effect on BP and heart rate (HR) dynamics in hypertensive rats [62, 63, 161].  
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4.2 AIM 
To date, there has been limited research evaluating the long-term effects of VNS on BP and 
associated cardiovascular complications in advanced-stage HTN in rats. The aim of this study is to 
investigate the effects of low-level, intermittent chronic VNS therapy on the long-term survival of 
hypertensive rats and to evaluate the impact of VNS therapy on BP control, HR dynamics, and 
structural cardiac properties. 
 
4.3 METHODS 
All experiments conform to the Guidelines for the Care and Use of Laboratory Animals (NIH 
publication No. 85-23, revised 1996) and the University of Minnesota guidelines for the care and 
use of animals. Prophylactic antibiotic (gentamicin sulphate; 10 mg/kg, i.m.) was given prior to 
each surgery. During the surgeries, rats were anaesthetized with isoflurane (5% for induction, 2% 
or 3.5% for maintenance) in oxygen (2 L/min for induction, 1 L/min for maintenance). The rat’s 
body temperature was maintained at 37ºC on a temperature-controlled surgery table. 
 
4.3.1 Experimental Design 
Five week old male DSS rats (Charles River Laboratories, Wilmington, MA) were fed a high 
salt (8% NaCl) diet to induce HTN, and this diet was maintained for the duration of the study (see 
Figure 4.1A). Four weeks after initiating the high salt diet, the hypertensive rats were implanted 
with vagus nerve stimulators (Model 103, LivaNova USA, Inc., formerly Cyberonics Inc., Houston, 
TX) and physiological telemetry devices (HD S11, DSI Inc., St. Paul, MN) and randomly divided 
into two groups: VNS (n = 9; functional VNS stimulators) and Sham (n = 9; non-functional VNS 
stimulators). One Sham rat was excluded from analysis because of the delayed recovery from 
surgery, resulting in n=8 for Sham.  At Week 6 (Baseline), the low-level VNS therapy was activated 
and applied for up to 8 weeks or until an endpoint (death or severe HTN-related events such as a 
stroke or hematoma) was reached. During VNS therapy, ECG and BP recordings were 
simultaneously captured through the DSI telemeters for both Sham and VNS rats. The event-free 
survival rate was calculated with respect to the start of VNS therapy at Week 6. A summary of the 
data analyses used, the time points selected, and the number of rats in each group can be found in 
Table 4.1. 
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Figure 4.1 (A) Experimental design. HTN was induced using a high salt diet (8% NaCl). At Week 
4, the rats were implanted with vagal nerve stimulators and DSI transmitters, and randomly divided 
into Sham (n = 8) and VNS (n=9) groups. VNS therapy was turned on at Week 6 and continuous 
BP and ECG was recorded until the end of the study. (B) Kaplan-Meier event-free survival curves 
for Sham and VNS rats are statistically different (P < 0.05). The dashed vertical line indicates the 
start of VNS therapy at Week 6. The number of rats remaining in each group is included along the 
x-axis. 
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Table 4.1 Summary of data analyses performed including time points and number of rats included 
in the analysis 
 Time Point 
Analysis Week 6 Week 7 Week 8 Week 9 Week 12 
Acute VNS Response  
4-h segment (Day
4h
 and 
Night
4h
) 
VNS Rats Only* 
VNS (n = 6)†   VNS (n = 6) † VNS (n = 2) † 
Longitudinal Analysis 
SBP, MAP, DBP, PP, 
HR, HRV 
12-h segment (Day
12h
 
and Night
12h
) 
Analysis uses all data from all rats and time points 
Circadian Rhythm 
24-h segment 
VNS (n = 9) 
Sham (n = 8) 
  VNS (n = 8) 
Sham (n = 5) 
 
BRS 
4-h segment (Day
4h
 and 
Night
4h
) 
VNS (n = 9) 
Sham (n = 8) 
VNS (n = 9) 
Sham (n = 8) 
VNS (n = 9) 
Sham (n = 6) 
VNS (n = 8) 
Sham (n = 5) 
 
* Only VNS rats with adequate ECG signal to identify stimulation intervals were used for analysis 
† Data presented in Chapter 5 of this thesis 
 
4.3.2 Vagus Nerve Stimulator Implantation 
The VNS pulse generator and cuff electrodes were implanted as described previously [125, 
126]. Briefly, the surgical regions on the back and the neck were shaved. Bipolar cuff electrodes 
were implanted through a small incision on the neck and placed around the right cervical vagus 
nerve and common carotid artery bundle. The pulse generator was implanted subcutaneously and 
positioned on the back of the rat. VNS was applied with a pulse frequency of 20 Hz, a pulse width 
of 500 μs, and an output current of 0.25 - 1.0 mA. The amplitude of the current was selected based 
on a stimulation level of sufficient strength to appear on the ECG but without causing an acute peak 
reduction in HR greater than 10% during the active phase of the stimulation cycle. Each VNS cycle 
consisted of an active phase, consisting of 14 seconds of full strength stimulation plus a 2-second 
ramp up and ramp down phase, followed by an inactive phase, 62 seconds in duration, resulting in 
a duty cycle of 22.5%.  
 
4.3.3 DSI Telemeter Implantation 
DSI transmitters were implanted as described previously [127]. Briefly, the chest and inner 
thigh were shaved and the transmitter pressure catheter was implanted through a small incision on 
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the inner left hind limb into the descending aorta via the left femoral artery. The two ECG leads 
were fixed subdermally on the chest muscle. After surgery, the rats were individually housed in 
cages where they were able to freely move about while receivers (model RPC1, DSI Inc.) connected 
to a computer via a Data Exchange Matrix (MX2, DSI Inc.) continuously collected data from each 
rat. The ECG and arterial BP data were collected at a sampling rate of 500 Hz throughout the study.  
 
4.3.4 Data Analysis 
4.3.4.1 Chronic Effects of VNS Therapy: Disease Progression 
Simultaneous ECG and BP data acquired from the DSI telemeters were averaged over 12-hour 
Day12h (7am-7pm) and Night12h (7pm-7am) intervals, defined by the light-dark cycle of the room. 
BP and HR measures, including systolic blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP), pulse pressure (PP), HR, and heart rate variability (HRV), were 
calculated.  
Baseline BP and HR parameters were quantified as the three-day average prior to the start of 
VNS therapy at Week 6. Individual values for Day12h and Night12h  intervals was compared to 
Baseline data to determine the relative change in BP (ΔSBP), HR (ΔHR), and HRV (ΔHRV) for 
each animal, as described previously [159]. The longitudinal data for Sham and VNS rats were 
individually fit with a linear regression to quantify the disease progression, and the slopes of the 
linear fits were averaged for Sham and VNS rats for comparison between groups.  
Circadian rhythm analysis was performed at Baseline and at Week 9. A 24-hour continuous 
segment of data was divided into 1-hour intervals and fit with a cosinor function using the following 
equation  
𝑌 = 𝑀𝐸𝑆𝑂𝑅 + 𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 ∗ cos(𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 ∗ 𝑋 + 𝐴𝑐𝑟𝑜𝑝ℎ𝑎𝑠𝑒), 
where X is the 1-hour average HR or BP from the Sham or VNS rats, MESOR is the mean value of 
the cosinor function, Amplitude is the difference between the peak value and the MESOR, and 
Acrophase is the phase shift. The Frequency was set to 0.2618 rad/hr, corresponding to a 24-hour 
period. 
 
4.3.4.2 Baroreflex Sensitivity 
The time domain baroreflex sensitivity (BRS) sequence method quantifies concordant changes 
in BP and HR. BRS analysis was analyzed from Week 6 to Week 9. The parameters for the BRS 
method were set to the following: a minimum sequence length of 16 consecutive beats, a minimum 
change in BP of 5 mmHg, and a R2 value threshold of 0.85. Baroreflex sensitivity (BRS) was 
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quantified using a traditional sequence method for Day4h  and Night4h intervals to compare 
autonomic tone in the hypertensive rats [162].  
 
4.3.4.3 Histology and Gross Morphology  
After reaching an endpoint of the in-vivo protocol, excluding death, the heart was extracted 
through a midline incision and immediately submerged in cold cardioplegic solution. The hearts 
were weighed and normalized to tibia length (HW/TL) as a measure of hypertrophy [159], and 
were then preserved in 10% formalin solution for histology studies. Sham (n = 8) and VNS (n = 6) 
hearts were embedded in paraffin, cut into 5 μm thick cross-sectional slices, and stained with 
Masson’s Trichrome. The stained heart slices were imaged using Nikon microscope (Model 
ECLIPSE Ni-E, Nikon Corporation, Tokyo, Japan) system at 4x magnification. NIS-Elements AR 
(version 4.51.01) software was used to scan each slide and export the images for post-processing.  
 
4.3.5 Statistics 
BP and HR data are presented as mean ± standard error. Cumulative event-free survival is 
presented using Kaplan-Meier curves, and the Log-Rank test was used to determine statistical 
significance. The acute effects of VNS at different time intervals were compared using repeated 
measures one-way ANOVA with Tukey’s multiple comparisons correction. The linear regression 
slopes for the longitudinal BP and HR measures were compared between Sham and VNS rats using 
one-way ANOVA. The circadian rhythm parameters were compared between Sham and VNS rats 
and Week 6 and Week 9 time points using two-way ANOVA with Tukey’s multiple comparisons 
correction. Finally, the structural effects were compared using simple linear regressions to compare 
structural measures as a function of survival for Sham and VNS rats. Statistical significance was 
determined at P < 0.05. 
 
4.4 RESULTS 
4.4.1 Baseline Parameters 
Baseline ECG (HR, HRV) and BP (MAP, SBP, DBP and PP) parameters show no significant 
differences between Sham and VNS rats (see Table 4.2). Specifically, Baseline HR (Sham: 386 ± 
5 bpm, VNS: 389 ± 5 bpm) and SBP (Sham: 192 ± 10 mmHg, VNS: 187 ± 8 mmHg) were similar 
between groups and are consistent with previously published parameters in hypertensive rats [159].   
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Table 4.2 Baseline parameters, presented as mean +/- standard error, for VNS (n=9) and Sham 
(n=8) rats calculated as a three day average prior to the start of therapy. 
Baseline Parameter Sham (n = 8) VNS (n = 9) P-value 
HR (bpm) 386 ± 5 389 ± 5 0.52 
HRV (%) 9.5 ± 0.6 9.8 ± 0.3 0.55 
SBP (mmHg) 192 ± 10 187 ± 8 0.65 
MAP (mmHg) 160 ± 9 155 ± 7 0.66 
DBP (mmHg) 131 ± 9 128 ± 6 0.7 
PP (mmHg) 61 ± 2 59 ± 3 0.63 
 
 
Figure 4.2 Baseline characteristics of Sham and VNS rats versus event-free survival times. Baseline 
SBP (A), MAP (B), DBP (C), PP (D), HR (E), and HRV (F) show no significant differences 
between groups demonstrating no significant influence on the differences observed in event-free 
survival times in Sham and VNS rats. 
 
4.4.2 Event-Free Survival Assessment 
Figure 4.1B shows the cumulative event-free survival rates of the Sham and VNS rats, with a 
significant improvement in survival of VNS rats (P < 0.05). The median survival improved by 78% 
in VNS rats with median survival times increasing from 23.5 (95% CI: 12 to 33) days for Sham 
rats to 42 (95% CI: 30 to 53) days for VNS rats. In addition, 2/9 VNS rats survived to the end of 
the study, whereas 0/8 Sham rats survived. Individual baseline parameters for Sham and VNS rats 
were plotted versus survival time, in days, to observe whether any baseline parameters factored 
into the survival times observed in the two groups (Figure 4.2). All parameters showed similar 
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ranges in both Sham and VNS rats at baseline, and did not contribute significantly to different 
observed in survival.  
To better understand possible factors contributing to the prolonged survival of VNS rats, we 
further evaluated the effects of VNS therapy on (1) chronic disease progression, (2) autonomic 
tone, and (3) structural properties of the heart.  
 
4.4.3 Impact of Chronic, Cyclic VNS on HTN Progression 
HTN progression in the Sham and VNS rats was quantified by the relative change in SBP 
(ΔSBP) and HR (ΔHR) over time with respect to baseline values during the Day12h and Night12h 
intervals. Figure 4.3A and 4.3B (left panels) shows that the progressive increase of ΔSBP due to 
HTN is attenuated in the VNS rats compared to the Sham rats, as is suggested by the growing 
separation in the ΔSBP curves over time. Indeed, the linear regression slopes in the Sham rats are 
significantly larger when compared to VNS rats during both the Day12h (Sham: 14.6 ± 2.0 
mmHg/week; VNS: 9.2 ± 2.3 mmHg/week; P < 0.05) and Night12h (Sham: 14.6 ± 1.7 mmHg/week; 
VNS: 8.8 ± 1.4 mmHg/week; P < 0.05) intervals.  
The circadian rhythm was evaluated at Week 6 and Week 9 (Figure 4.3C and 4.3D, 
respectively). While similar circadian rhythm characteristic were observed for both Sham and VNS 
rats at Week 6, three weeks of VNS therapy resulted in a significantly increased average baseline 
(MESOR) value in Sham rats in comparison to the VNS rats (see * in Figure 4.3D), providing 
further evidence of an attenuation in the rise in SBP due to VNS.  
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Figure 4.3 Relative changes in SBP (ΔSBP) as HTN progresses. ΔSBP as a function of time and 
slopes of the linear regressions are shown for Sham and VNS rats during the (A) Day12h and (B) 
Night12h intervals. Circadian rhythm of SBP for Sham and VNS rats are shown for Week 6 (C) 
and Week 9 (D). * indicates statistical significance between Sham and VNS rats. 
 
Longitudinal analyses were performed on additional BP measures including MAP, DBP, and 
PP, which are shown in Figures 4.4-4.6. The disease progression of MAP, shown in Figure 4.4 
panel A and B for Day12h and Night12h intervals respectively, shows an attenuation in ΔMAP for 
VNS rats in comparison to Sham rats. This attenuation, quantified by the slope of the linear 
regression, is significant during the Night12h interval (Sham: 13.1 ± 1.6 mmHg/week; VNS: 8.5 ± 
1.1 mmHg/week; P < 0.05) but not the Day12h interval (Sham: 13.7 ± 1.7 mmHg/week; VNS: 9.2 
± 1.1 mmHg/week; P = 0.1029). Circadian rhythm analysis at Week 6 and Week 9 are shown in 
panels C and D. There are no differences in circadian characteristics at baseline. However, after 
three weeks of therapy, there is a significant separation in the MESOR value, with Sham rats having 
a significantly higher MAP MESOR value than the VNS rats.  
The progression of DBP from Week 6 to Week 9 during Day12h and Night12h are shown in 
Figure 4.5, panel A and B. Although there is a separation in the ΔDBP, it is not significantly 
different between Sham and VNS rats during either the Day12h or Night12h interval. The results of 
the circadian rhythm analysis are shown in panels C and D for Week 6 and Week 9 respectively. 
Again, there were no significantly differences in the circadian rhythm characteristics at baseline, 
and after three weeks of therapy there was a significant difference in the MESOR values between 
the Sham and VNS rats. The Sham rats had a significantly larger DBP MESOR value. 
Figure 4.6 shows the progression of PP in the Sham and VNS rats over the first three weeks of 
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therapy. ΔPP showed similar results, with no significant differences in ΔPP between groups during 
either the Day12h or Night12h interval. In addition, the circadian rhythm analysis produced similar 
results with no differences observed at Week 6 and a significant increase in the PP MESOR value 
for Sham rats compared to VNS rats at Week 9.   
 
 
Figure 4.4 Relative changes in MAP (ΔMAP) as HTN progresses. ΔMAP as a function of time 
and slopes of the linear regressions are shown for Sham and VNS rats during the (A) Day12h and 
(B) Night12h intervals. Circadian rhythm of SBP for Sham and VNS rats are shown for Week 6 
(C) and Week 9 (D). * indicates statistical significance between Sham and VNS rats. 
 
 
Figure 4.5 Relative changes in DBP (ΔDBP) as HTN progresses. ΔDBP as a function of time and 
slopes of the linear regressions are shown for Sham and VNS rats during the (A) Day12h and (B) 
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Night12h intervals. Circadian rhythm of SBP for Sham and VNS rats are shown for Week 6 (C) and 
Week 9 (D). * indicates statistical significance between Sham and VNS rats. 
 
 
 
Figure 4.6 Relative changes in PP (ΔPP) as HTN progresses. ΔPP as a function of time and slopes 
of the linear regressions are shown for Sham and VNS rats during the (A) Day12h and (B) Night12h 
intervals. Circadian rhythm of SBP for Sham and VNS rats are shown for Week 6 (C) and Week 9 
(D). * indicates statistical significance between Sham and VNS rats. 
 
Figure 4.7A and 4.7B (left panel) quantifies the relative change in HR over time during the 
Day12h and Night12h intervals in the Sham and VNS rats. The slopes of the ΔHR linear regression, 
although greater in Sham rats, were not significantly different during either interval (Figures 4.7A 
and 9B, right panel). Circadian rhythm of HR showed no difference between Sham and VNS rats 
at Week 6 (Figure 4.7C), but after three weeks of VNS therapy, the MESOR value for Sham rats 
was significantly higher compared to VNS rats (see * in Figure 4.7D).  
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Figure 4.7 Relative changes in HR (ΔHR) as HTN progresses. ΔHR as a function of time and 
slopes of the linear regressions are shown for Sham and VNS rats during the (A) Day12h interval 
and (B) Night12h intervals. Circadian rhythm analysis of HR for Sham and VNS rats are shown for 
Week 6 (C) and Week 9 (D). * indicates statistical significance between Sham and VNS rats. 
 
4.4.4 Impact of VNS on Autonomic Regulatory Function 
 The effects of VNS on autonomic tone were evaluated through HRV and BRS measures 
and are presented in Figure 4.8. The relative change in HRV during Day12h and Night12h intervals 
are shown for Sham and VNS rats in Figure 4.8A and 4.8B respectively. The results show that VNS 
significantly affects the dynamics of HRV over time. Specifically, ΔHRV was maintained or 
slightly increased in VNS rats as opposed to the Sham rats, which experienced negative ΔHRV as 
HTN progressed. Indeed, the slopes of the ΔHRV linear regression were significantly decreased 
over three weeks of therapy for Sham (Day12h: -1.5 ± 0.3%; Night12h: -0.8 ± 0.3 %) but not for VNS 
rats, where ΔHRV remained relatively stable over time (Day12h: 0.01 ± 0.3%; Night12h: 0.1 ± 0.2%). 
Finally, Figure 4.8C and 4.8D shows BRS values measured weekly from Week 6 to Week 9, 
showing significantly increased BRS values in VNS rats compared with Sham rats at Week 7 during 
both Day4h and Night4h and at Week 8 during the Night4h interval. This acute increase in BRS for 
VNS treated rats was not present at Week 9, where BRS values were similar between VNS and 
Sham rats. 
 
54 
 
 
Figure 4.8 Relative changes in HRV (ΔHRV) as HTN progresses. ΔHRV as a function of time and 
slopes of the linear regressions are shown for Sham and VNS rats during the (A) Day12h interval 
and (B) Night12h intervals. BRS was quantified during the Day4h (C) and Night4h (D) intervals for 
Week 6 through Week 9. * indicates statistical significance between Sham and VNS rats. 
 
4.4.5 Impact of VNS on Structural Changes in the Hypertensive Heart 
The results of the gross morphology and histology studies are shown in Figure 4.9 as a function 
of survival along with the corresponding linear regression from Sham and VNS rats. Examples of 
stained cardiac cross-sections for Sham and VNS rats are shown in Figure 4.10. Figure 4.9A shows 
the relationship of HW/TL over time, which was significantly different between groups. Sham rats 
had a decrease in HW/TL (-0.0027 ± 0.0019 g/cm/day) while VNS rats exhibited an increase in 
HW/TL as a function of survival time (0.0038 ± 0.0013 g/cm/day; P < 0.05). In addition, 
HW/diameter (Figure 4.9B) showed a similar result with Sham rats having a decrease in 
HW/diameter over time (-0.0024 ± 0.0006 g/cm/day), while VNS rats showing an increase over 
time (0.0001 ± 0.0006 g/cm/day; P < 0.05).  Although changes were observed in HW, individual 
thickness measures of the RV and LV free wall as well as septum showed no significant differences 
between treatment groups (Figure 4.9D-F). In addition, no changes were seen in diameter or body 
weight between Sham and VNS rats as a function of survival (Figure 4.10). Finally, chronic VNS 
therapy resulted in no changes in the percent of fibrosis in the cardiac cross-sections as seen in 
Figure 4.9C. 
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Figure 4.9 Gross morphology and histology studies. The effects of VNS on cardiac structural 
properties – (A) HW/TL, (B) HW/diameter, (C) percent fibrosis, (D) right ventricle (RV) and (E) 
left ventricle (LV) free wall thickness and (F) septum thickness – as a function of survival rate 
along with corresponding linear regression fits. 
 
 
Figure 4.10 Examples of the cardiac cross sections from the Sham (A) and VNS (B) hearts stained 
with Masson’s Trichrome. The cardiac fibrosis can be seen in blue around the vessels and within 
the interstitial space. (C) Cross section diameter and (D) body weight as a function of survival times 
with corresponding linear regressions for Sham and VNS rats. 
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4.5 DISCUSSION 
The major finding of this study was a significant improvement in the long-term survival of 
hypertensive rats treated with VNS therapy, with median event-free survival increasing by 78% for 
VNS rats in comparison to Sham rats. This study further evaluated the effects of VNS various 
cardiovascular, hemodynamic, and structural cardiac properties that may contribute to prolonged 
survival of VNS rats with respect to Sham rats. Our results can be summarized as follows: (1) 
chronic VNS slowed the progression of HTN through and an attenuation in the rise of SBP, 
demonstrated in the linear regression analysis during the day and night intervals and the MESOR 
shift in circadian rhythm, (2) chronic VNS preserved autonomic balance as HTN progressed by 
maintaining elevated HRV and BRS measures in the VNS rats compared to Sham rats, and (3) VNS 
significantly altered cardiac structure increasing heart weight, but did not alter the amount of 
fibrosis in the hypertensive hearts.  
 
4.5.1 Chronic Disease Progression 
VNS therapy has been demonstrated to have beneficial long-term effects in hypertensive 
animal models. Our previous chronic study demonstrated the impact of low-level intermittent VNS 
on BP through a long-term effect resulting in a reduction in the spontaneous rise in BP after 4 weeks 
of therapy in hypertensive rats [159].  Here, a significant attenuation was observed after just three 
weeks of VNS therapy. This attenuation in rising SBP by Week 9 may play a role in the delay in 
the onset of adverse events in hypertensive rats.  
The characteristics of BP control in Sham and VNS rats were further evaluated using cosinor 
analysis to compare circadian rhythms in SBP and HR, which are mediated by cyclic variations in 
autonomic activity [163]. Although there was a significant increase in the MESOR value for Sham 
in both HR and SBP, the amplitude and acrophase of the cosinor parameters were not significantly 
different. In addition, this abnormality in circadian rhythm is associated with an increased risk of 
cardiovascular risk and target organ injury [164]. Through stimulation of the parasympathetic 
nervous system, VNS may help maintain regular cyclic BP control.  
 
4.5.2 Autonomic Regulatory Function  
HRV is commonly used in clinical practice as a prognostic indicator of cardiovascular 
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conditions. In the case of HTN and heart failure (HF), autonomic dysfunction results in decreased 
HRV. It is postulated that stimulation of the parasympathetic nervous system, through right cervical 
VNS, has the potential to rebalance the autonomic nervous system (ANS) by direct increasing 
parasympathetic activity and reflexively reducing sympathetic activity. Indirect measures of 
autonomic balance, such as HRV and BRS, have been assessed in numerous studies showing a 
restoration of autonomic balance and improved prognostic indications for the VNS-treated 
group.[69, 165] Here, we demonstrate results consistent with those previously seen. VNS preserved 
HRV values from Week 6 through Week 9, while Sham rats experienced a large reduction in HRV 
during both the day and night intervals. Our results also showed an acute increase in BRS for several 
weeks, indicating improved BP and HR control. In HTN, chronic structural changes in the heart 
and vasculature alter the function of the arterial baroreceptors decreasing their sensitivity to 
fluctuations in BP, ultimately decreasing BRS [166]. Overall, the beneficial effects on HRV and 
BRS in the VNS rats may be mediated through balancing autonomic activation and altering 
structural changes in vasculature, which may ultimately contribute to the prolonged survival in 
VNS rats.  
 
4.5.3 Structural Cardiac Effects 
Our results demonstrate that VNS had a significant impact on hypertrophy with increased HW 
as survival times increased in hypertensive rats. In addition, opposite trends in LV and RV free 
wall thicknesses were observed, with VNS showing a reduction over time. However there is no 
change in the amount of fibrosis between Sham and VNS rats. Although, without sufficient overlap 
of Sham and VNS data at early and late time points in the survival curve, assessing the progression 
of structural changes in the treated and untreated heart is challenging. In addition, the increased 
survival of VNS rats means these rats were older and exposure to high-salt diet for a longer duration 
at the time the hearts were analyzed, which may influence the results observed in this study. 
VNS may be altering the progression of cardiac remodeling in response to increasing BP levels. 
Previously, DSS rats have been shown to advance to later stages of HTN rapidly while on 8% NaCl 
with significant hypertrophy and LV dilation as early as 11 and 15 weeks of age, respectively [167]. 
With respect to our experimental design, those time points correspond to Week 6 and Week 10. 
VNS therapy may delay or alter the time course of HHD in these rats. Another important factor to 
consider is the advanced-stage of HTN in the rats in this study. Nguyen et al. demonstrated that 
even in the early stages of HTN, the heart undergoes structural and electrical remodeling [168]. 
The rats in this study had well established HTN at the beginning of VNS therapy and were 
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continued on a high salt diet for the remainder of the study. Intervening in the earlier stages of HTN 
may provide restorative or preventative structural cardiac effects. Further studies are necessary to 
fully understand the effects of VNS therapy on HHD in various stages of HTN. 
Numerous other mechanism of VNS therapy have been evaluated in HTN and cardiovascular 
disease models which could be contributing to the improved survival, attenuation in the 
spontaneous rise in BP, and improved autonomic tone observed in this study. Additional 
mechanisms through which VNS has been hypothesized to provide therapeutic effects include anti-
adrenergic effects, anti-inflammatory pathways, activation of nitric oxide release in the heart, and 
inhibition of the renin-angiotensin system. Suppressing central sympathetic outflow through 
activation of vagal nerve afferent fibers can lead to a reduction in sympathetic nervous system 
activity, resulting in reductions in HR, vascular resistance, and arterial BP. Several studies have 
demonstrated the ability of VNS to reduce systemic inflammation through the activation of the 
cholinergic anti-inflammatory pathway, reducing cytokine synthesis and the inflammatory 
response [69, 108]. Inflammation is associated with HTN, although the cause-and-effect 
relationship still remains unclear. It is hypothesized that inflammation can lead to endothelial 
dysfunction and increased oxidative stress, which promote the development and progression of 
HTN [107]. VNS has also been shown to directly activate the nitric oxide pathway producing nitric 
oxide in the ventricles, altering cardiac electrophysiology and decreasing arrhythmia susceptibility 
[101]. Another proposed mechanism of VNS is inhibition of the renin-angiotensin system through 
afferent vagal nerves, resulting in a reduction in renin in the kidneys and marked reduction in plasm 
angiotensin II levels [69, 114].  
 
4.5.4 Limitations 
This study has several limitations. First, there were nine and eight rats in the VNS and Sham 
groups, respectively, and they were in advanced stages of HTN by Week 6 when therapy was 
initiated for VNS rats. Further studies need to be conducted to evaluate the effects of VNS therapy 
in various stages of HTN to investigate the preventative and restorative potential of VNS in 
controlling BP and addressing adverse cardiovascular effects associated with HTN. Second, acute 
effects and autonomic evaluation through BRS measures was limited to four-hour data segments 
during day and night intervals. Future work will include quantifying these parameters over larger 
data segments to better understand the progression due to HTN as well as changes due to variation 
in autonomic tone based on time of day.  In addition, the high salt diet (8% NaCl) produced an 
aggressive cardiovascular insult that resulted in the death of all Sham rats; further studies are 
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needed to evaluate the effects of slightly lower salt diet (e.g. 4%).  
 
4.6 CONCLUSION 
Overall, our results are consistent with previous studies that show potential for VNS to provide 
therapy for HTN and HTN-induced heart disease. This study shows a strong beneficial effect of 
VNS therapy on long-term survival, BP control, and autonomic tone. These results motivate 
additional studies to investigate the mechanism of VNS in treating HTN and determine optimal 
stimulation parameters for therapeutic effects. 
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Chapter 5 
 
Acute cardiovascular and hemodynamic effects of vagus nerve 
stimulation in conscious hypertensive rats 
 
5.1 INTRODUCTION  
In this chapter I present the methods and result for evaluating the acute effects of vagus nerve 
stimulation (VNS) in hypertensive rats over the course of chronic therapy to evaluate two main 
questions: (1) what happens acutely in response to VNS and (2) does this effect persist over the 
course of therapy in our chronic study.  
Several researchers have evaluated acute effects of VNS quantifying hemodynamic, 
autonomic, and inflammatory responses in various animal models. Specifically, acute VNS was 
shown to have anti-inflammatory effects and result in a significant reduction in heart rate (HR) in 
rats with pulmonary arterial hypertension (HTN) [169]. In addition, VNS has been demonstrated 
to reduce blood pressure (BP) acutely when targeting the aortic depressor nerve within the vagus 
nerve [62, 63]. However, the majority of studies were conducted with continuous VNS while the 
animal was under anesthesia. These experimental conditions raise two fundamental questions: (1) 
are the effects of VNS different when applied continuously versus intermittently, and (2) what are 
effects anesthesia and cold the effect of VNS either be diminished or exaggerated? 
 
5.2 AIM 
The aim of this study is to better understand the acute effects of low-level intermittent VNS in 
hypertensive rats through evaluation of cardiovascular and hemodynamic response while the rat is 
conscious. Here, changes in mean and variability measures of BP and HR are quantified to better 
understand physiological changes by acute activation of the vagus nerve. 
 
5.3 METHODS 
All experiments were approved by the University of Minnesota Animal Care and Use 
Committee and were conducted in accordance with Institutional and NIH guidelines (NIH 
publication No. 85-23, revised 1996). 
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5.3.1 Experimental Model 
HTN was induced in Dahl salt-sensitive (DSS) rats (n = 6, 5 weeks old, male) using high salt 
8% NaCl diet (S10001, Research Diets, Inc., New Brunswick, NJ, USA), which was maintained 
for the entire duration of the study. After 5 weeks of high salt diet, the rats underwent surgery to 
implant physiological telemeters (HD-S11, Data Sciences Inc. (DSI)) and vagal nerve stimulators 
(Model 103, Cyberonics Inc.) as described previously [159]. Briefly, the telemetry device was 
placed in the abdomen of the rat with a pressure catheter inserted into the left femoral artery for 
continuous BP monitoring and two leads were placed subdermally on the chest wall of the rat for 
continuous ECG monitoring. The VNS stimulator was placed under the skin on the back of the rat, 
and a lead connected to the pulse generator was implanted through a midline incision on the neck. 
The bipolar cuff electrodes were then placed around the right cervical vagus nerve and carotid 
bundle. The rats were given at least one week to recover prior to the start of VNS therapy.  
 
5.3.2 Vagus Nerve Stimulation 
The low-level VNS was applied intermittently with a pulse frequency of 20 Hz, a pulse width 
of 500 us, and with an “On” and “Off” time of 14 and 66 seconds respectively. Each stimulation 
period has a 2-second ramp up and ramp down interval, which are added to the “On” period 
resulting in a 22.5% duty cycle (Figure 1, top panel). The amplitude of the VNS stimulation was 
set individually for each rats to influence HR by no more than 10%, resulting in current values of 
0.25-0.75 mA. Rats were individually housed and free to move about their cages while being 
continuously monitored for the remainder of the study.  
 
5.3.3 Data Analysis 
BP and ECG traces were collected at a sampling rate of 500 Hz. Four-hour data segments were 
acquired for day (10am-2pm) and night (10pm-2am) intervals for each rat at Week 6 (Day 1 of VNS 
therapy), Week 9 (after 3 weeks of therapy), and Week 12 (after 6 weeks of therapy). Data was 
segmented into the following windows: “Pre,” “VNS On,” “Post 1,” and “Post 2” (Figure 5.1). “Pre” 
was defined as the 7-second segment prior to VNS therapy. “VNS On” was defined as the 14 seconds 
during which VNS was applied, excluding the 2-second ramp up and ramp down intervals. “Post 1” 
and “Post 2” were defined as two consecutive 7-second segments immediately after VNS. For each 
data segment, the following values were calculated: systolic blood pressure (SBP), blood pressure 
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variability (BPV), HR and heart rate variability (HRV), and contractility, which was determined as 
the maximum slope of the derivative of the BP waveform (dP/dtmax). BPV was calculated as 
BPV = σBP / BP, 
where σBP and BP are the standard deviation and mean of the BP data, respectively, and BP was 
measured as the systolic BP peak value. HRV was calculated as 
HRV = σHR / HR, 
where σHR and HR are the standard deviation and mean of the HR data, respectively. Due to the 
noisy nature of the 2-lead ECG data, HR was derived using pulse interval calculated from the BP 
trace, as described in [170]. Data are presented as percent change relative to the “Pre” stimulation 
interval. All data analysis was performed using custom MATLAB code.  
 
 
 
Figure 5.1 An example of the data segmentation into “Pre”, “VNS On”, “Post 1” and “Post 2”  
intervals for one episode of VNS in the rat. The top panel is the representative stimulation including 
the ramp up and ramp down periods. The second panel shows the recorded ECG trace with VNS 
artifacts visible during the “VNS On” segment. The third and fourth panels show the corresponding 
BP and BP derivative (dP/dt) traces, respectively. 
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5.3.4 Statistical Analysis 
One-way ANOVA was used to compare values at each segment (“Pre,” VNS On,” “Post 1,” and 
“Post 2”). Post hoc analysis was performed with Tukey’s multiple comparison correction. 
Significance was determined at P < 0.05. 
 
5.4 RESULTS 
The custom MATLAB program was developed to analyze ECG and BP data traces for 
approximately 400 VNS episodes per rat (Figure 5.1) Day and night intervals were combined 
together to obtain average values for all measured parameters.  
 
5.4.1 Week 6 Acute VNS Response 
Mean HR derived from the BP waveform was calculated for each interval during Day 1 of VNS 
therapy and showed no significant changes before, during, or after VNS therapy (Figure 5.2). 
However, VNS significantly increased HRV during the “VNS On” interval when compared to the 
“Pre” interval. Nevertheless, the HRV decreased back to baseline levels immediately after VNS was 
turned off, so that both HRV during “Post 1” and “Post 2” have similar values as during the “Pre” 
interval (Figure 5.2B). Similarly, the mean SBP response of the VNS rats showed no significant 
changes before, during and after VNS therapy (Figure 5.2D). However, there was a significant 
increase in BPV during the “VNS On” period, which returned to “Pre” values immediately after 
VNS therapy is turned off (Figure 5.2E).  
Contractility was assessed by quantifying the maximum rate of change of the pressure waveform 
(dP/dtmax). With increased vagus activity, contractility is known to decrease. However, during low-
level VNS therapy in our study, no significant acute changes (less than 1% change) were observed 
in the intervals analyzed. Figure 5.2C shows no change in dP/dtmax during any intervals surrounding 
episodes of VNS therapy.  
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Figure 5.2 Acute (A) HR, (B) HRV, (C) Contractility (dP/dtmax), (D) SBP, and (E) BPV responses 
during VNS therapy in hypertensive rats (n = 6) for  “Pre”, “VNS On”, “Post 1” and “Post 2” 
intervals at Week 6, the first day of VNS therapy. † indicates statistical significance in mean values 
between intervals 
 
5.4.2 Week 9 Acute VNS Response 
Figure 5.3 shows the percent change in HR, HRV, contractility, SBP, and BRS with respect to 
the “Pre” interval values. Both SBP and contractility slightly decrease during the “VNS On” 
interval, which is significantly lower with respect to the “Post 2” interval where a slight overshoot 
from pre-stimulation values was observed. In contrast, HRV and BPV were significantly increased 
during “VNS On” with respect to both pre- and post-stimulation values, and immediately returned 
to pre-stimulation values after the cessation of therapy. However, HR was not significantly affected 
by the low-level VNS therapy.  
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Figure 5.3 Acute (A) HR, (B) HRV, (C) Contractility (dP/dtmax), (D) SBP, and (E) BPV responses 
during  VNS therapy in hypertensive rats (n = 6) for  “Pre”, “VNS On”, “Post 1” and “Post 2” 
intervals at Week 9, after 3 weeks of VNS therapy. † indicates statistical significance in mean 
values between intervals. 
 
5.4.3 Week 12 Acute VNS Response 
At Week 12, the remaining VNS rats were evaluated for their acute cardiovascular and 
hemodynamic response to stimulation (Figure 5.4). No significant differences were observed in 
SBP, BPV, HR, or contractility values. However, HRV demonstrated a similar response to Week 
6 and 9, with a significant increase in HRV during “VNS On” in comparison to the “Post 2” interval. 
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Figure 5.4 Acute (A) HR, (B) HRV, (C) Contractility (dP/dtmax), (D) SBP, and (E) BPV responses 
during  VNS therapy in hypertensive rats (n = 2) for  “Pre”, “VNS On”, “Post 1” and “Post 2” 
intervals at Week 12, after 6 weeks of VNS therapy. † indicates statistical significance in mean 
values between intervals. 
 
5.5 DISCUSSION 
This study evaluated the acute effects of low-level, intermittent VNS in conscious hypertensive 
rats. The major finding of this paper were the following: (1) no significant acute changes in HR were 
induced during the “VNS On” period, when compared to the “Pre” and “Post” intervals, (2) SBP 
and contractility were both significantly reduced during VNS compared to the “Post 2” interval only 
at Week 9, and (3) both HRV and BPV were significantly increased acutely during the “VNS On” 
period.  
 
5.5.1 The Effect of VNS on Mean Cardiovascular and Hemodynamic Responses 
During VNS, there were no significant acute changes in HR in the hypertensive rats. Indeed, in 
this study we used low-level VNS therapy that intentionally does not drastically alter either HR or 
BP. This effect can be controlled through the selection of stimulation parameters. Specifically, 
varying the amplitude has been shown to induce significantly different acute cardiovascular 
responses [58, 171]. The stimulation settings and subsequent effects depend on the goal of the 
therapy. Here, VNS was initially titrated to cause no more than a 10% drop in HR during day time 
stimulation to provide low-level therapy while reducing side effects. Therefore, the short therapy 
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duration in combination with the low-level stimulation likely led to no significant changes in mean 
HR during acute episodes of VNS therapy.  
VNS only caused small changes in SBP during Week 9 (between “VNS On” and “Post 2” 
intervals), but otherwise caused no changes at Week 6 or Week 12. Previously, several studies have 
shown an acute decrease in BP du rot selective VNS therapy in anesthetized rats, which was 
accompanied by a reduction in mean HR [62, 63]. This reduction was smaller when applying non-
selective VNS using the same stimulation parameters [62]. Here, intermittent VNS stimulation is 
applied non-selectively at a low level with a 22.5% duty cycle. Such a short therapy duration and 
low amplitude may not have time to elicit a significant change in the SBP measures with respect to 
pre-stimulation levels before stimulation is turned off. Also, in previous studies, the acute effects of 
VNS on SBP and HR have been demonstrated in healthy rats [61-63], while here, we have evaluated 
the effect of acute VNS in hypertensive rats. HTN has been associated with an imbalance in the 
autonomic nervous system (ANS) with increased sympathetic nerve activity and a decrease in 
parasympathetic nerve activity [7]. This imbalance in the ANS could lead to a different response to 
acute stimulation, which may require higher amplitude or longer duration for stimulation to elicit a 
response in the altered autonomic state.   
 
5.5.2 The Effect of VNS on Variability in Cardiovascular and Hemodynamic Responses 
The results of the acute stimulation show a strong positive effect on HRV. HRV is a common 
prognostic indicator used in the clinic to evaluate the cardiac condition of patients. In disease states, 
such as HTN and heart failure, the overactive sympathetic nervous system reduces the autonomic 
control of cardiac function, decreasing HRV. Increases in HRV indicate better autonomic balance, 
through either a suppression of the sympathetic activity or activation of the parasympathetic activity, 
and can be indicative of therapeutic efficacy. The acute changes in HRV observed here could have 
an additive effect, contributing to the long term beneficial effects of VNS therapy.  
In addition to changes in HRV, acute changes in BPV were also observed in the hypertensive 
rats. Traditionally in the clinic, increases in BPV are associated with increased risk [172]. However, 
this effect on BPV observed here has been shown before, with variability in BP occurring in response 
to HRV induced through vagal activation [173]. This response observed in this study, returns to 
baseline values at the cessation of therapy. 
 
68 
 
5.5.3 The Effect of VNS on Contractility 
The results show a small but significant change in contractility during stimulation. However, 
this effect is only observed at Week 9 in conjunction with the decrease in SBP. Week 6 and Week 
12 measures had no differences in contractility between intervals. It is commonly known that 
enhanced parasympathetic activity has a negative inotropic effect on the heart. This effect has been 
recently demonstrated using various VNS parameters applied for 30 seconds in anesthetized sheep 
[171]. There are several key differences however that can explain this difference observed in this 
study including the species, disease state, and duration of stimulation. Short VNS duration in our 
study may result in a smaller cumulative effect on the contractility of the heart in the conscious 
hypertensive rats. Increasing duration or amplitude of stimulation may result in a measurable change 
in contractility along with changes in other cardiac parameters including HR.  
 
5.5.4 The Effect of VNS over Time 
VNS continued to show a strong acute effect on HRV even after three weeks of therapy, 
increasing HRV as stimulation was applied. In addition to changes in HRV, BPV was also 
significantly increased, but to a lesser extent. This result has been observed previously as BPV 
reflexively increases acutely in response to vagal activation [173, 174]. The acute change in HRV 
is evident of enhance parasympathetic activity or decreased sympathetic activity, and may 
contribute to chronic therapeutic effects of VNS. This effect on HRV was even seen at Week 12 
indicating that VNS therapy still elicits the same cardiovascular response and suggests therapy 
remains efficacious even after six weeks. 
 
5.5.5 Limitations 
There are several limitations for the current data analysis. First, only 4-hour day and night 
segments were analyzed from each of the VNS-treated rats. Larger data segments may give more 
information about the acute changes and whether time of day and related autonomic balance affects 
the acute cardiovascular and hemodynamic response to VNS.  Second, this study only evaluates the 
acute response to one set of VNS parameters. Future studies will investigate the effects of various 
intermittent VNS parameters on the cardiovascular and hemodynamic responses. Finally, further 
evaluation of HRV using spectral analyses can provide indication so sympathetic and 
parasympathetic tone.  
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5.6 CONCLUSION 
Quantifying acute cardiovascular and hemodynamic changes due to VNS in conscious animals 
can help provide a better understanding of VNS therapy and physiological responses to acute 
parasympathetic activation. The small acute changes observed during intermittent VNS could be 
additive, leading to beneficial chronic changes in BP and HR control [159]. Evaluating the acute 
effects can help further the understanding of VNS in its application as a chronic therapy and assist 
in parameter selection and optimization for providing beneficial effects for treating HTN.  
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Chapter 6 
 
Part 1 Conclusions 
6.1 CONCLUSIONS 
Hypertension (HTN) is an extremely prevalent condition which now affects almost half of the 
adults in the United States. Further, with the aging population, the number of patients with HTN is 
expected to continue to rise. Although numerous treatment options exist, including 
antihypertensive medications, there are still an alarming number of patients, approximately half of 
all hypertensive patients, who do not achieve target blood pressure (BP) levels and as a result face 
increased risk of cardiovascular disease (CVD) and end organ damage. Numerous clinical 
limitations contribute to this statistic including comorbidities, drug resistance, non-compliance, and 
intolerance. There is a significant clinical need to develop new therapies that can help overcome 
limitation associated with the current clinical approach to help improve patient outcomes.  
The aim of Part 1 of this dissertation is to evaluate the potential of low-level, intermittent vagus 
nerve stimulation (VNS) applied to the right cervical vagus nerve to treat HTN and associated 
cardiovascular complications that can addresses limitations with current treatment approaches. 
Through direct activation of the parasympathetic nervous system, VNS provides a novel approach 
to target the imbalance in the autonomic nervous system (ANS), which is known to play a critical 
role in the pathogenesis of HTN. These studies investigated acute and chronic hemodynamic and 
cardiovascular responses of dahl salt-sensitive hypertensive rats treated with and without VNS 
therapy. Further, this dissertation aims to evaluate the electrophysiological and structural cardiac 
effects of VNS therapy.  
The results of these studies demonstrate the potential for low-level, intermittent VNS to provide 
effective therapy for HTN and hypertension-induced heart disease (HHD). The initial chronic study 
evaluating the effects of four weeks of VNS therapy yielded promising results which led us to 
further evaluate VNS by extending therapy to quantify its impact on long-term survival. The results 
from both studies revealed numerous beneficial effects in hypertensive dahl salt-sensitive rats 
including improved long-term survival, blood pressure control, preserved autonomic tone, and 
beneficial electrophysiological cardiac remodeling.  
VNS shows a progressive effect on BP resulting in a significant attenuation in the rise in 
spontaneous BP, suggesting chronic therapy is necessary to have a measurable effect. In addition, 
the impact observed on BP suggests a predominately afferent signaling driven effect modulating 
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the systemic balance of sympathetic and parasympathetic activity. The modulation of the ANS was 
demonstrated through both acute and chronic studies showing VNS acutely increasing heart rate 
variability (HRV) during stimulation, and confirmed through the preservation of HRV as HTN 
continued to progress in dahl salt-sensitive rats.   
VNS therapy demonstrated cardioprotective effects in HHD.  Beneficial results have been 
hypothesized to be due to a reduction in heart rate (HR), lowering the metabolic demand of the 
heart. Here, the low-level VNS therapy does not significantly alter HR, with initial stimulation 
titrated to affect the HR by no more than 10%. However, beneficial cardiac electrophysiological 
effects were still evident, consistent with the anti-arrhythmic effects previous demonstrated in other 
cardiovascular disease models. Specifically, VNS reduced action potential duration (APD), 
maximum slope of the APD restitution curve, APD spatial dispersion, and the complexity of ex-
vivo induced ventricular arrhythmias. This suggests the role of both afferent and efferent 
stimulation in the cardioprotective effects demonstrated in this model.  
Overall, VNS shows promise as a novel therapy for HTN and HHD that can address limitations 
associated with current treatment approaches. Specifically, VNS targets the imbalance in the ANS 
inherent in HTN and can possibly provide an effective alternative to patients with resistance HTN. 
In addition, as a device-based therapy, patients and physicians may have less concern with 
compliance. Therapy can also be titrated to limit or avoid undesirable side effects, with advances in 
therapy continuing to improve targeted stimulation. Finally, VNS provides a multifaceted therapy 
providing the primary effect of BP control, likely mediated through predominately afferent 
signaling, as well addressing secondary cardiovascular effects, mediated through a combination of 
afferent and efferent stimulation.  
 
6.2 FUTURE WORK 
The positive results demonstrated here motivate further evaluation of VNS as a therapy for HTN. 
Future studies include modifying the severity of HTN and the stage in which therapy is initiated. 
Lowering the percentage of the high salt diet fed to the dahl salt-sensitive rat will slow the 
progression HTN and allow for longer in-vivo evaluation of VNS on hemodynamic and 
cardiovascular parameters and its impact on the pathophysiology of HTN. Additional studies can be 
performed to investigate the impact of VNS therapy initiated at varying points in the disease. 
Specifically, can VNS initiated at lower BP levels when HTN is first established, prevent the rise in 
BP and subsequent cardiac remodeling? Conversely, can VNS therapy initiated at a later stage of 
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HTN, at a lower salt intake and thus slower progression, lead to a reversal in the rise in BP levels 
and reversal in adverse cardiac remodeling? 
Additional studies are needed to determine the appropriate stimulation parameters and 
paradigms to optimize therapy for HTN and HHD.  There are numerous variables that can be set for 
VNS therapy including current amplitude, pulse width, frequency, duty cycle, selective or non-
selective, right- or left-sided stimulation, invasive or non-invasive, and stimulation site (i.e. the 
cervical or auricular branch). Across VNS research, disease states and stimulation parameters have 
widely varied, leading to variable results, which begs the question: which stimulation parameters are 
optimal for achieving the dual effect on BP and cardiovascular function? Acute and chronic studies 
are needed to expand on our knowledge and understanding of the mechanisms of VNS therapy. 
Acute studies can provide a means to evaluate a large parameters space to quantify hemodynamic 
and cardiovascular responses and can be then used to inform chronic studies evaluating efficacy of 
VNS in hypertensive models. Furthering our understanding of VNS parameters and associated 
mechanisms can help improve the efficacy of VNS therapy and tailor its application to specific 
disease states and individual patients.  
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Part 2 
 
Investigating novel mapping techniques to identify 
rotors in cardiac arrhythmias 
 
OBJECTIVE 
The objective of Part 2 of my dissertation is to evaluate the accuracy and robustness of novel 
mapping techniques – multiscale frequency, kurtosis, Shannon entropy, and multiscale entropy – 
to identify regions of rotors and provide translation to clinical applications in intracardiac mapping. 
These techniques are validated using ex-vivo optical mapping studies where electrical activity can 
be directly visualized and clinical limitations such as shortened time series duration and reduced 
spatial resolution can be simulated. The ability of these novel techniques in identifying rotors to 
outperform a clinically available mapping approach, dominant frequency, is demonstrated using 
optical mapping movies of cardiac arrhythmias with stationary and meandering rotors. In addition, 
the consistent identification under simulated clinical limitations further highlights the potential for 
these techniques to be translated to clinical use where improved signal processing techniques can 
help further our understanding of the generation and maintenance of atrial fibrillation and 
ultimately improve ablation procedure success rates and terminate the arrhythmia.  
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Chapter 7 
 
Background 
7.1 ATRIAL FIBRILLATION 
Atrial fibrillation (AF) is characterized by unorganized electrical activity in the atrium resulting 
in inefficient contractions and reduced cardiac output (Figure 7.1). AF is further categorized into 
patients with paroxysmal, persistent, and long-standing AF. Paroxysmal AF refers to episodes of 
AF that are able to terminate on their own, lasting less than seven days. In contrast, persistent AF 
persists for more than 7 days at a time and usually requires treatment to return to normal sinus 
rhythm. Long-standing AF is defined as AF occurring continuously for more than 12 months [175]. 
AF is the most common cardiac arrhythmia; with high incidence affecting between 2.7 and 6.1 
million individuals in the United States alone and over 30 million people worldwide [2, 176]. In 
addition, AF is a prognostic indicator for stroke, heart failure, and even death [176]. Further, AF 
and its complications pose a large burden on the U.S. health care system, accounting for over $6.6 
billion each year [177, 178]. Many patients could benefit from targeted treatments to reduce the 
occurrence of these arrhythmias and the accompanying risk factors.  
 
75 
 
 
Figure 7. 1 Electrical activity in the heart during normal sinus rhythm (A-C) and AF (D-E). Adapted 
from Lip et al. 2016  [179]. 
 
7.2 CURRENT TREATMENT APPROACHES 
The continuing challenges in fully understanding the etiology of AF makes currently available 
treatments suboptimal with regards to using pharmacological, percutaneous and surgical 
interventional approaches. 
7.2.1 Pharmacotherapy 
Antiarrhythmic drugs are the first line of treatment for patients with AF, with the goal of 
maintaining normal sinus rhythm and preventing AF-related complications. Acute management of 
AF uses pharmacological agents to restore normal sinus rhythm or reduce rapid ventricular rates 
[180]. Long-term management, however, focuses more on managing symptoms of AF, such as 
thromboembolism, and improving quality of life [181]. However, pharmacological treatment for 
AF has major limitations in that this approach does not always provide adequate means of control 
and can lead to intolerable side effects, such as organ toxicity and bleeding [175, 182]. New 
pharmacotherapy approaches are needed for acute and chronic management of AF. Further research 
in understanding the pathophysiology of AF can lead to better medication options with improved 
efficacy and safety profiles [182]. 
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7.2.2 Ablation 
There is a growing interest in catheter ablation therapy to terminate AF by targeting specific 
regions in the atrium including the triggers and substrates responsible for initiating and maintaining 
AF.  Recently, ablation procedures attempt to isolate triggers responsible for the initiation of AF. 
In the case of paroxysmal AF, the pulmonary veins are targeted as they are often the source of 
ectopic beats, triggering episodes of AF. A depiction of pulmonary vein isolation (PVI) is shown 
in Figure 2.2. For paroxysmal AF, the PVI procedure is successful in terminating AF in ≥ 70% of 
patients [4]. However, in patients with persistent or long-standing AF, this PVI procedure only 
results in a success rate of 20-30% after a single procedure and 51% for repeat procedures [5, 6, 
183]. Ablation procedures in non-paroxysmal AF have had limited success as the underlying 
mechanisms are not fully understood. Recently, rotor-based ablation strategies have been 
demonstrated to outperform PVI ablation alone [15-17], but more research is needed to develop 
techniques that can accurately identify and target rotors and further evaluate whether rotors are 
suitable targets for ablation. 
 
 
Figure 7.2 Depiction of the pulmonary vein isolation ablation procedure using mapping and 
ablation catheters to electrically isolate the pulmonary veins. Adapted from Chowdhury et al. 2009 
[184]. 
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The remainder of this chapter will focus on using ablation to target drivers of AF to terminate 
the arrhythmia. Current electrophysiology mapping techniques are described below as well as novel 
techniques being developed to overcome limitations of the current clinical approaches to more 
accurately identify the substrate maintaining AF. 
 
7.3 DRIVERS OF ATRIAL FIBRILLATION 
For AF to persist in the heart, there needs to be both a trigger and a substrate. The trigger, such 
as an ectopic beat or premature atrial contraction (Figure 7.3, left panel), initiates the arrhythmia, 
while the substrate is responsible for maintaining the arrhythmia [185-187]. Cardiac arrhythmias, 
like AF, may be mediated by a variety of mechanisms, ranging from focal automaticity to 
macroreentry to more complex states where organized activity may be difficult or even impossible 
to define. In AF, the characteristic finding is global disorganization of activity in the associated 
chamber [188], and multiple hypotheses have been proposed since the 1950s regarding the 
pathophysiology underlying both the initiation and maintenance of the arrhythmia. Defining the 
mechanisms of arrhythmia maintenance, however, is more difficult as there are likely multiple 
mechanisms responsible for AF. In addition, as the duration of AF increases, as seen in patients 
with non-paroxysmal AF, the atria undergo electrical and structural remodeling leading to more 
complex mechanism responsible for the maintenance of the arrhythmia. Currently the two leading 
hypotheses for the maintenance of AF are (1) multiple wavelet theory and (2) functional reentry 
(i.e. rotors) which are shown in Figure 7.3. 
 
 
Figure 7. 3 Diagrams of the current hypotheses in AF initiation and maintenance – ectopic beat 
(left), rotors or functional reentry (middle), and multiple wavelets (right). Adapted from Guillem, 
2016 [189]. 
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7.3.1 Multiple Wavelet Reentry 
Multiple wavelet theory was first defined by Moe et al. in 1959 and states that AF is maintained 
by a critical number of independent wavelets in a heterogeneous medium defined by the atrial size, 
mass, conduction velocity and refractory period [190, 191]. The wavelets randomly propagate and 
collide resulting in chaotic, fibrillatory conduction [186, 190]. Originally, it was hypothesized that 
the critical number of wavelets necessary to maintain the arrhythmia was more than 20 wavelets. 
Allessie later provided evidence that fewer, only 4 to 6, independent wavelets could maintain the 
arrhythmia [192, 193]. Currently, the multiple wavelet theory is accepted by most clinical 
electrophysiologists because of the results of the maze ablation procedure, which 
compartmentalized the atrial tissue to terminate AF. By removing the ability for multiple randomly 
propagating wavelets to exist in the atria, the arrhythmia was terminated, providing evidence for 
the multiple wavelet theory [192, 194]. 
 
7.3.2 Rotors 
Another proposed mechanism of AF maintenance is spatially localized focal sources, or rotors 
[189], which was proposed as the driver of AF in the 1970s and later demonstrated experimentally 
in 1990 by Davidenko et al. [195, 196].  Rotors are an organized source of functional re-entry. The 
electrical activity at the core of the rotor rotates around the singularity point which is excitable but 
not yet excited tissue [197]. These rotors can remain stationary or can meander and drift through 
the atrium which contributes to irregularities in electrical recordings [198]. The trajectory of these 
meandering rotors can be complex and depend on the electrical and structural properties of the 
tissues nearby. Rotors have definitive characteristics such as extreme wavefront curvature at the 
core, an excitable and precessing core and a highly variable reentrant wavelength, with an often-
undetectable excitable gap [199]. Precession of rotors may contribute towards global 
disorganization evident in AF, and indeed they are the source of fibrillatory wavefronts that control 
surrounding tissues passively thereby both initiating and maintaining AF [188, 200]. Due to rotor 
movement, locating these active sites for ablation presents significant challenges that necessitate 
more robust algorithms for mapping [189].  There is still significant debate around the theory of 
rotors. However, numerous optical mapping studies have demonstrated the existence of rotors [190, 
201, 202]. These findings have led to the development of multiple methods aiming to use 
electrogram data to reproduce these optical mapping results and, in turn, determine potential critical 
ablation targets for treating AF [188, 197, 203, 204]. However, clinical studies have not been 
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reproducible, thus calling into question the ability to identify rotors using traditional electrogram 
approaches.  
 
7.4 ELECTROPHYSIOLOGICAL MAPPING FOR ABLATION PROCEDURES 
Rotors provide a target for ablation therapy and terminating AF [197, 203, 204]. However, the 
current challenge is in accurately locating and ablating the regions in the atrium where the rotors 
exist. Currently, clinical electrophysiology studies are performed to record intracardiac 
electrograms from the endocardial surface of the atria. The electrical activity is captured using 
various mapping catheters placed in key regions of the atria in order to interpolate and reconstruct 
activity throughout the atria. These signals are then integrated and analyzed using an 
electroanatomical mapping systems such as the CARTO System (Biosense Webster, Diamond Bar, 
CA), EnSite Navx (Abbott, Chicago, IL), and RHYTHMIA HDx (Boston Scientific, Marlborough, 
MA). These systems provide physicians with real-time 3D anatomical views of the atria while 
positioning the catheter in various regions of the atria. Signal processing techniques can then be 
used in real-time or offline to generate 3D maps of the substrate from the unipolar or bipolar 
electrogram recordings to identity regions of interest for ablation. However, there are numerous 
clinical limitations associated with intracardiac mapping which makes the identification of rotors 
or other target regions maintaining AF difficult to identify.  
Challenges in rotor identification stem from clinical limitations of electrophysiological studies 
including short electrograms recordings, low spatial resolution, and the presence of meandering 
rotors. Despite advances in cardiac mapping technologies, clinical intracardiac mapping can only 
capture a limited number of simultaneously recorded electrograms. During these procedures, the 
number of spatial locations that are able to be mapped are limited, resulting in non-uniform atrial 
recordings and a low spatial resolution. Also, while maneuvering the recording catheters within the 
atrium, poor contact of the electrode to the atrial tissue may not provide sufficient signal strength 
to identify atrial substrates. Finally, in addition to limitations to capturing adequate electrograms, 
the presence of meandering rotors can increase the complexity of rotor identification. Meandering 
rotors may only briefly be captured through intracardiac mapping. In combination with the duration 
and spatial limitations, meandering rotors prove challenging to accurately identify and locate. 
Several techniques have previously been developed to analyze intracardiac electrograms to 
characterize rotors. These techniques include dominant frequency (DF) [205-208], local activation 
time (LAT) using isochronal maps [208, 209], complex fractionated atrial electrogram (CFAE) 
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mapping [208, 210, 211], and phase analysis using phase singularity evaluation [200, 208, 212], 
which have been evaluated in experimental and clinical applications, but have had varying success 
due to numerous limitations.  
 
7.4.1 Local Activation Time 
Local activation time maps visualize the timing of the excitation wavefront at multiple 
locations in the atrial tissue. The map generated is based on tissue conductions and repolarization 
times determined from the morphology of extracellular potentials [213]. In these activation maps, 
isochrones are lines used to depict simultaneous activation in the atria with propagation of the 
wavefront moving perpendicular to the isochrones [213]. This method is fairly simple to implement 
on high-amplitude, high-quality intracardiac electrograms which allows for automatic annotation 
of electrogram morphology to generate activation maps similar to those shown in Figure 7.4 [214]. 
However, this technique has several key limitations such as poor spatial resolution and 
susceptibility to noise. Inaccurate activation times can results from low-amplitude signals, external 
noise, and sufficient fragmentation requiring the signal to be annotated manually [214].  
 
 
Figure 7.4 Example of LAT maps from a patient with persistent AF showing multiple views of 
the atria. Adapted from Arunachalam et al. 2017 [215]. 
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7.4.2 Dominant Frequency 
One approach that has been previously studied using optical mapping is dominant frequency 
(DF) analysis [205, 206]. DF, the peak frequency in the time series spectrum, has been used to 
identify focal sources in fibrillatory activity. The high frequency regions, indicating rapid and 
periodic activation, are believed to represent likely substrate responsible for the maintenance of AF 
[216]. An example of a DF map from a patient with persistent AF is shown in Figure 7.5. DF can 
easily be calculated using electrical recordings from the atrium, requiring only activation 
information. Mandapati et al. identified sources with the maximum DF in isolated sheep hearts 
using optical mapping and bipolar electrode recordings. Their results demonstrated that by using 
DF alone, discrete sites of high frequency periodic activity can rapidly be identified [206]. 
Expanding DF analysis to clinical data, Sanders et al. used this technique to identify regions of high 
frequency activity, and guide catheter ablation procedures in humans. In this study, patients with 
paroxysmal AF had an 89% success rate. However, for the 13 patients with persistent AF, the 
arrhythmia was not terminated [205]. The DF approach alone may not be suitable to provide 
accurate rotor localization due to several limitations including temporal instability, artifacts can 
significantly distort DF maps, and the rotor core cannot be specifically identified [217]. 
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Figure 7.5 Example of DF mapping in a patient with persistent AF. (A) Recorded electrograms 
along with the corresponding power spectra. (B) DF map with arrows pointing to regions of high 
frequency. CS indicates coronary sinus; IVC, inferior vena cava; LA, left atrial; LIPV, left 
inferior pulmonary vein; LSPV, left superior pulmonary vein; RA, right atrial; RSPV, right 
superior pulmonary vein. Adapted from Guillem et al. 2013 [218]. 
 
7.4.3 Complex Fractionated Atrial Electrograms 
In AF, rapid electrical activity emanating from the rotor propagate out into the periphery and 
become fractionated as the wavefront interacts with anatomical and functional inhomogeneity in 
the tissue. CFAE quantifies the fractionation occurring in the wavefront and identifies reentrant 
activity by having at least one of the following criteria: continuous electrical activity, at least two 
deflection, cycle length less than 120 ms, and an amplitude less than 0.05mV [210, 219, 220].  The 
electrograms can be classified into 4 types: C0 (non-fractionated), C1 (fractionated with periodic 
activity), C2 (both fractionated and non-fractionated periodic activity), and C3 (high frequency and 
continuous atrial activity) shown in Figure 7.6. 
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Figure 7.6 (A) Schematics (left) and corresponding recorded atrial signals (right) of the four 
common types of CFAEs. Adapted from Schilling, 2012 [221]. (B) An example of CFAE mapping 
in a patient with persistent AF along with atrial recordings of various typtes of CFAEs captured in 
the atria. Adapted from Jadidi et al. 2013 [222]. 
 
Early high-density cardiac mapping studies demonstrated the electrogram fractionation in AF 
[223, 224], which lead to clinical investigations whether PVI with CFAE ablation would 
outperform PVI alone. The Substrate and Trigger Ablation for Reduction of AF (STAR-AF) II 
Trial enrolled 100 patients with high-burden paroxysmal or persistent AF and randomized to PVI 
alone or PVI with CFAE ablation. However this study failed to demonstrated added benefit with 
the CFAE ablation [225]. These results have brought into question the validity of the CFAE 
approach in identifying regions of atria substrate maintaining AF. Further, numerous key 
limitations of CFAE mapping exist including low reproducibility, low specificity of the active 
regions, and high occurrence of identifying passive regions, which are not actively contributing the 
maintenance of AF [219, 224].  
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7.4.4 Phase Analysis 
Phase analysis mapping provides insights into the spatiotemporal organization of fibrillation 
[226]. Phase maps are created by calculating the instantaneous phase of the electrogram using the 
Hilbert transform. This transformation into the phase domain allows for the signal to be depicted 
from –π to +π revealing patterns in fibrillatory activation as shown in Figure 7.7 [226, 227]. 
Specifically, the point at which the phases converge, called singularity points, are of specific 
interest as they may identify functional or anatomical rotational activity. Traditionally phase 
mapping is performed with high-spatial resolution in ex-vivo optical mapping experiments in 
animals using voltage-sensitive dyes. However, this approach is not feasible in the clinical due to 
the toxicity of the voltage sensitive dyes. Instead, intracardiac mapping using basket catheters and 
recently non-invasive body surface electrodes has been used to capture electrical activity and derive 
phase in human AF as demonstrated in Figure 7.7 [209, 228]. Although this technique offers the 
advantage of temporal and spatial resolution to visualize the sources of fibrillatory activity, there 
are several limitations with implementing this technique in the clinic. First, unipolar electrograms, 
representing a summation of local activity, are not optimal for calculating localized activation 
patterns. In addition, this technique can result in misleading phase calculations if the T-waves are 
captured. Finally, the results are dependent on having a high spatial resolution, and often times the 
number of electrodes and spacing in clinical studies are inadequate and require interpolation to 
generate phase maps [226].  
 
Figure 7. 7 Example of a phase map derived from body surface electrodes. Adapted from Sohal et 
al. 2015 [219]. 
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Many recent advances have been made in quantitative intraprocedural signal analysis to guide 
the selection of ablation targets [208]. However, there is no solid evidence that any of these 
approaches can successfully identify rotor core zones or pivot point locations to terminate AF based 
on ablation at those identified sites, and no significant improvements in ablation outcomes were 
observed [225, 229].  
 
7.5 NOVEL MAPPING TECHNIQUES 
There is a clear need for robust spatio-temporal techniques that can consistently identify rotors 
or areas of abnormal electrical activity using unique electrical characteristics of the pivot point that 
can be applied to clinical intracardiac mapping. This can be accomplished through the development 
of techniques that are validated using high resolution optical mapping studies and numerical 
simulations where clinical limitations such as decreased electrograms duration and reduced spatial 
resolution can be simulated. 
Recently, several new signal analysis approaches have been developed – Shannon entropy (SE) 
[230, 231], multi-scale frequency (MSF) [232], kurtosis (Kt) [233], and multi-scale entropy (MSE) 
[234] – to identify the pivot points of rotors in the case when rotors can be easily visualized using 
optical mapping techniques. These proposed techniques utilize different cardiac signal 
characteristics, other than local activation, to uncover the intrinsic complexity of the electrical 
activity in the rotors, which are not taken into account in current mapping methods.  
 
7.5.1 Multiscale Frequency 
MSF estimation is a novel approach that incorporates various physiological frequencies present 
in the heart, and is not limited to single frequency analysis as with DF maps. This technique uses a 
robust algorithm to estimate instantaneous frequency using eight log-Gabor filters. Each of the 
eight filters are one octave apart and designed with a bandwidth of 2√2. The center frequencies of 
these filters can be chosen to span the appropriate physiological range for heart rate. The remaining 
frequency components are combined to calculate a wide range local MSF estimate, 𝜌, using the 
weighted summation of eight log-Gabor filter pairs. MSF is calculated as follows: 
𝜌 = 𝜌𝑜 [∑ 𝑞𝑖
𝑁−1
𝑖=1
]
−1
∑ 2𝑖+0.5𝑞𝑖+1
𝑁−1
𝑖=1
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Where 𝑞𝑖 is the output of the i
th log-Gabor filter and 𝜌𝑜 is the center frequency of the first log-
Gabor filter. Due to the chaotic nature of the rotor and presence of additional underlying 
frequencies, the MSF value is expected to be different at the core of the rotor when compared to 
the periphery [232].  
 
7.5.2 Shannon Entropy 
SE is a statistical measure of expected information content based on the distribution amplitude 
of values in a histogram. The voltage signals at each spatial location/pixel is binned according to 
its voltage intensity into a histogram. The relative probability density, 𝜌, is defined as the number 
of counts in an intensity bin divided by the total count in all bin. SE is calculated as follows: 
𝑆𝐸 =  ∑ 𝑝𝑖 log2 𝑝𝑖
𝑁−1
𝑖=0
 
Where N is the number of amplitude bins, and p is the probability of any sample falling within a 
particular amplitude bin. At the core of the rotor, the interference of wavefronts and the presences 
of several physiological frequencies could lead to a reduction in the amplitude of the voltage signal, 
therefore creating a narrower distribution of voltage intensities. The narrower distribution 
corresponds to a higher certainty and lower SE at the core of the rotor. In the periphery, there is 
less interference as the wave propagates through, leading to a broader distribution in voltage 
intensities and therefore a higher SE value [230]. 
 
7.5.3 Kurtosis 
Kt is a higher order statistical measure, the 4th central moment, dealing with non-Gaussian or 
possible nonlinear processes. Kt is a measure of peakedness of a probability density function of a 
real-valued random variable. For each voltage trace at each pixel, the intensities are binned to create 
a voltage histogram which can then be used to determine the peakedness of the probability density 
function. Distributions with a narrower distribution and higher peak will have a higher Kt value in 
comparison to those with a broad distribution and minimal peak. The 4th central moment is 
calculated as follows: 
𝐾𝑡(𝑥(𝑡)) = 𝐸 {(
𝑥(𝑡) − 𝐸{𝑥(𝑡)}
𝜎𝑥
)
4
} 
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Where E is the expected value or mean of the time signal x(t), and 𝜎𝑥 is the variance. Due to the 
expected narrow distribution at the core of the rotors, the core is expected to be identifiable with a 
high kurtosis value with respect to the periphery [233].  
 
7.5.4 Multiscale Entropy 
MSE approach employs a sample entropy algorithm over multiple time scales to fully capture 
the intrinsic complexity of non-stationary time series data. This method uses a nearest neighbor 
moving average kernel to better capture the complexity of a non-stationary time series data. This 
approach contains “memory” by accounting for previous and future time series values while 
computing the nearest neighbor average. A time scale factor, τ, represents the time scaling in the 
forward and reverse directions. For this analysis, the nearest neighbor moving-averaged time series 
is calculated using τ = 3. Using the moving-averaged time series, the number of matched vectors 
within the timer series were calculated for vector lengths of m and m+1. For this analysis, m = 2. 
Two samples were considered to match if the distance between the vectors is less than r, where r is 
chosen to be 0.2 times the standard deviation of the raw time series. MSE is calculated as the sample 
entropy of the total number of matched template vectors as shown below:  
𝑀𝑆𝐸 =  − ln (
𝑛(𝑚 + 1, 𝑟)
𝑛(𝑚, 𝑟)
) 
 
Where n(m+1,r) is the total number of matched vectors of length m+1, and n(m,r) is the total 
number of matched vectors of length m [234].  
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Chapter 8 
 
Novel quantitative analytical approaches for rotor identification 
and associated implications for mapping 
 
8.1 INTRODUCTION 
Chapter 8 presents the results of the validation study demonstrating the potential of four novel 
mapping techniques – multiscale frequency (MSF), kurtosis (Kt), Shannon entropy (SE), and 
multiscale entropy (MSE) – to identify stationary and meandering rotors in ventricular arrhythmias 
captured in ex-vivo optical mapping studies in a rabbit heart. The study presented in this chapter 
evaluates the performance and robustness of MSF, Kt, SE, and MSE techniques with respect to 
several clinical limitations: decreased time duration and reduced spatial resolution. In addition, 
Chapter 8 discusses the clinical implications and translation of these techniques. 
Cardiac arrhythmias may be mediated by a variety of mechanisms, ranging from focal 
automaticity to macroreentry to more complex states where organized activity may be difficult or 
even impossible to define. In certain arrhythmias, including atrial fibrillation (AF) and ventricular 
fibrillation (VF), the characteristic finding is global disorganization of activity in the associated 
chamber [188]. In the case of AF, for example, multiple hypotheses have been proposed since the 
1950s regarding the pathophysiology underlying both the initiation and maintenance of the 
arrhythmia. One mechanism that has been of particular interest is rotors, or regions of functional 
reentry, as have been demonstrated using optical mapping ex-vivo studies [190]. These findings 
have led to the development of multiple methods aiming to use electrogram data to reproduce these 
optical mapping results and, in turn, determine potential critical ablation targets for treating AF 
[188, 197, 203, 204]. However, clinical studies have not been reproducible, thus calling into 
question the ability to identify rotors using traditional electrogram approaches; and whether these 
area, if identified, truly reflect ablation targets.  
While the study of rotors has largely been focused on the treatment and understanding of AF, 
investigators have suggested that functional reentry may be relevant in some ventricular 
arrhythmias. Previous work has demonstrated that the underlying mechanism for certain 
experimental examples of ventricular tachycardia (VT) and VF in structurally normal hearts may 
in fact be functional reentry [235-238]. In addition, transitions between monomorphic VT, 
polymorphic VT, and VF may be subtended by shifts in the core size of isolated rotors during a 
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given arrhythmia [237, 239]. Thus, functional reentry likely subtends ventricular arrhythmogenesis 
in clinical examples of monomorphic VT. Therefore methods to define rotors using an electrogram-
guided approach may have clinical relevance for the treatment of ventricular arrhythmias as well. 
Several techniques have previously been developed to analyze intracardiac electrograms to 
characterize rotors. These techniques include dominant frequency (DF) [205-208], local activation 
time using isochronal maps [208, 209], complex fractionated electrogram mean index mapping 
[208, 210, 211], and phase analysis using phase singularity evaluation [200, 208, 212]. However, 
none of these techniques were successfully implemented in clinical settings due to various 
limitations [230]. Thus, there is a clear need for robust spatial-temporal techniques that can 
consistently identify rotors.  
Recently, several new signal analysis approaches have been developed – SE [230, 231], MSF 
[232], Kt [233], and MSE [234] – to identify the pivot points of rotors in the case when rotors can 
be easily visualized using optical mapping techniques. These proposed techniques utilize different 
cardiac signal characteristics, other than local activation, to uncover the intrinsic complexity of the 
electrical activity in the rotors, which are not taken into account in current mapping methods. 
However, applications of experimental data regarding the relevance of rotors has been challenging, 
in part, due to several clinical limitations associated with intracardiac mapping including short 
duration electrogram recordings, low spatial resolution, and the presence of meandering rotors.  
 
8.2 AIM 
In this paper, we seek to determine whether our recently developed techniques, including MSF, 
SE, Kt, and MSE, can be used to successfully identify rotors in arrhythmia episodes captured using 
optical mapping data and show potential for translation to clinical intracardiac electrograms 
identifying targets for ablation. Specifically, we seek to overcome the following challenge: (1) 
limitations in attaining simultaneous data from spatially distant locations; (2) electrogram data, 
which looks at local activation, fundamentally looks at different information than optical mapping, 
which looks at both depolarization and repolarization; and (3) temporal variability in the geographic 
location of rotors making interpretation of individual electrograms obtained at different points in 
time difficult to interpret. Our results may help characterize the utility of different signal processing 
approaches to defined regions of organized activity in more complex arrhythmias.  
 
90 
 
8.3 METHODS 
Optical mapping studies were performed on two isolated rabbit hearts as described previously 
[240, 241]. All procedures were approved by the University of Minnesota Animal Care and Use 
Committee and were conducted in accordance with Institutional and NIH guidelines. Episodes of 
ventricular tachycardia were induced using burst pacing, and two examples of rotors were used: (1) 
a single stationary rotor and (2) figure-of-8 reentry with one stationary and one meandering rotor. 
Movies were captured for a duration of 3 seconds at a rate of 600 frames per second with 64 x 64 
pixel resolution using voltage-sensitive dye and 12-bit CCD cameras. In each frame, the 
background fluorescence was subtracted and spatial (3 x 3 pixels) and temporal (5 frames) conical 
convolution filters were used to increase the signal-to-noise ratio.  
The phase movies were generated using the Hilbert transform, which calculates instantaneous 
phase allowing for the visualization of the depolarized and repolarized tissue. Gray et al. 
demonstrated that phase movies allow for the clear identification of the pivot point as the location 
at which all phases meet (phase singularity). Phase movies serve as a gold standard for locating the 
rotor in the examples presented [134]. Using phase maps, the singularity points were traced frame 
by frame to obtain a final pixel map representing the “true” location of the rotor pivot point. This 
map was used as a comparison for the identification of the pivot points for the five approaches 
described in Table 8.1. Specifically, DF and MSF were determined in the frequency domain. SE 
and Kt characterize the voltage intensities at each pixel. In addition, the time-series morphology 
and complexity were quantified using MSE. All analysis was performed using a custom-written 
MATLAB (Mathworks, Inc., Natick, MA) program.  
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Table 8.1 Summary of signal processing techniques 
 
 
8.3.1 Rotor Identification and Quantification 
Receiver operating characteristic (ROC) curves were constructed for all techniques using 
corresponding 2D maps generated from the original 3 second, 64 x 64 pixel movies. Specifically, 
the corresponding MSF, SE, Kt, and MSE values for each 2D map ranged from 1% to 99%, and 
the optimal point on each ROC curve, corresponding to the highest sensitivity and specificity, was 
identified as demonstrated in Figure 8.1. These points were used to define individual thresholds for 
the identification of rotor pivot points for each technique. 
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Figure 8.1 Receiver operator characteristic curves for the MSF, SE, Kt, and MSE techniques with 
the identification threshold varying from 0.01 to 0.99. The circles on each curve indicates the 
identification threshold for the 3-second duration time series for each mapping technique.   
 
The pixels in the 2D maps corresponding to the pivot point of the rotor were determined based 
on the individual thresholds for each MSF, SE, Kt, and MSE techniques, and compared with the 
“true” rotor location, to calculate the accuracy of each technique. Specifically, the number of pixels, 
as well as their location, were identified to determine the number of true positive (TP), true 
negatives (TN), false positives (FP), and false negatives (FN). From this data, accuracy was 
calculated as: 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁
 
The accuracy of each approach was calculated for various time series durations (3 seconds, 2 
seconds, 1 second, and 0.5 seconds) and spatial resolutions (64 x 64, 32 x 32, 16 x 16, and 8 x 8 
pixels) using the sliding window analysis. To determine the effect of decreased time series duration 
on the accuracy, the duration of the original optical mapping movies were decreased from 3 seconds 
down to 2, 1 and 0.5 seconds using a 0.5 second sliding window (Figure 8.2) which resulted in 3 
2-second times series, 5 1-second time series, and 6 0.5-second time series. The figure below 
depicts how the analysis was performed. In addition this analysis approach was also applied to the 
spatial resolution data with the 64x64 pixel data. Uniformly removing pixels from the original video 
to decrease spatial resolution resulted in 4-32x32 pixel movies, 16-16x16 pixel movies, and 64-8x8 
pixel movies. A similar process was then used to calculate optimal thresholds and optimal 
accuracies for each technique, which were defined separately for each reduced time series duration 
and spatial resolution.  
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Figure 8.2 Schematic of the sliding window duration analysis for the simulated clinical limitation 
or reduced time series. A sliding window of 0.5 seconds was applied to the data to get multiple 
time series of 2, 1 and 0.5 second durations. 
 
8.4 RESULTS 
8.4.1 Identification of the Pivot Point in a Single Stationary Rotor 
A snapshot of the phase movie from a single stationary rotor is shown in Figure 8.3A, where 
different colors represent different phases of an action potential, and the singularity point is seen 
where all phases converge [234]. Figure 3B shows the “true” location of the pivot point identified 
from the phase movie. Representative examples of times series, power spectrums, and voltage 
intensity distributions are shown in Figure 3D for the core and periphery of the rotor (pixels ‘1’ and 
‘2’ from Figure 8.3A).  
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Figure 8.3C shows a corresponding 2D DF map calculated for a rotor showing a single DF = 
7.8 Hz. Note that the DF approach cannot distinguish between the pivot point and periphery despite 
the clear differences in the time series data (Figure 8.3D).  
 
 
Figure 8.3 An example of a single stationary rotor from optical mapping of a rabbit heart. (A) 
Snapshot of the phase movie of the single stationary rotor with the depolarizing wave front shown 
in red. The pivot point and periphery of the rotor are identified by ‘1’ and ‘2’ respectively. (B) Pixel 
map showing the “true” location of the pivot point identified from the phase movie. (C) 2D DF 
map generated from the single stationary rotor showing a single DF of 7.8 Hz. (D) Representative 
examples of the time series, power spectrums, and voltage intensity distributions from the pivot 
point (location ‘1’) and periphery (location ‘2’) of the rotor demonstrating differences in signal 
characteristics. 
 
The 2D maps from MSF, SE, Kt, and MSE for the original stationary rotor (64 x 64 pixels, 3 
seconds) are shown in Figure 8.4A. Note that each of these techniques can clearly identify the core 
of the rotor, which is clearly associated with maximum (for the MSF, Kt, and MSE) or minimum 
(for SE) values when compared with the periphery of the rotor.  
The ability of these new approaches to identify the core of the rotor can be explained using the 
properties of the signal at the core and periphery (Figure 8.3D). The MSF approach accounts for 
various underlying physiological frequencies that are present at the core but not in the periphery. 
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This results in a higher MSF value at the pivot point (16.1 Hz) in comparison to the periphery (9 
Hz). The SE approach is based on the broadness of the distribution of voltage intensities at each 
pixel location. As is shown in Figure 8.3D, the pivot point of the rotor has a narrower distribution 
(SE = 5.7) than the periphery (SE = 7.2). The Kt approach uses the same data, but assesses the 
“peakedness” of the distribution. The narrow distribution at the core resulted in the more peaked 
distribution (Kt = 4.8) in comparison to the periphery (Kt = 1.7). The final approach, MSE, 
quantifies the complexity of the time series data. Regular voltage traces in the periphery result in a 
low MSE = 0.24, while at the core of the rotor MSE = 0.59 due to the irregularity in the voltage 
time series.  
 
8.4.1.1 Pivot Point Identification for Shorter Duration of Time Series 
Figure 8.4B evaluates the performance of MSF, SE, Kt and MSE approaches to identify the 
pivot point of the stationary rotor for progressively shortened durations of optical mapping data. A 
duration of 0.5 seconds was the shortest duration considered, which captures approximately 4 local 
activation-repolarization cycle. The results are shown as 3D contour plots to highlight the 
magnitude of the peak identifying the rotor as well as artifacts in the periphery and its relation to 
the times series duration. The x and y coordinates correspond to the (64 x 64) spatial resolution, 
and the z coordinate corresponds to different MSF, SE, Kt, and MSE values. As the duration of the 
data decreases from 3 seconds down to 2, 1 and 0.5 seconds, the amplitude identifying the stationary 
peak is reduced. However, the pivot point of the rotor is still distinguishable for all four approaches. 
Note that the SE and MSE approaches are associated with the presence of artifacts around the 
border, which may affect the performance of the approaches as the duration decreases further.  
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Figure 8.4 (A) 2D maps calculated for the 3 sec optical mapping video of the single stationary rotor 
using MSF, SE, Kt, and MSE approaches. (B) 3D contour plots demonstrate the ability of the 
techniques to identify the pivot point of the rotor for reduced arrhythmia durations of 2 sec, 1 sec, 
and 0.5 sec. The x and y coordinates correspond to (64x64) spatial resolution, and the z coordinate 
corresponds to the MSF, SE, Kt, and MSE values. 
 
8.4.1.2 Pivot Point Identification for Reduced Spatial Resolution 
Figure 8.5 evaluates the ability of the MSF, SE, Kt, and MSE approaches to identify the pivot 
point of the stationary rotor for progressively reduced spatial resolutions. As can be seen from 
Figure 8.5, all four techniques are able to correctly identify the pivot point of the stationary rotor.  
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Figure 8.5 2D maps from MSF, SE, Kt, and MSE identifying the single stationary rotor for reduced 
spatial resolutions of 32x32 (left), 16x16 (middle), and 8x8 pixels (right). 
 
To quantify the results presented in Figures 8.4 and 8.5, the location associated with the pivot 
point was identified for the MSF, SE, Kt, and MSE approaches and compared with the true pivot 
point location. Figure 8.6 quantitatively compares the performance of the mapping techniques in 
the identification of the pivot point of the rotor for reduced time series duration (Panel A) and 
spatial resolution (Panel B). The top panels show the accuracy of each technique using the 
individual threshold values that were determined for the original 3 second time series with 64 x 64 
spatial resolution. These results show stable accuracy for the entropy approaches, SE and MSE. 
However, both MSF and Kt techniques have a large reduction in accuracy as the duration decreases. 
The individual thresholds for each technique were then optimized for each duration and spatial 
resolution to calculate optimal thresholds (middle panels) as well as corresponding optimal 
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accuracy for each technique (bottom panels). The results in Figure 8.6 show that optimal accuracy 
improves the ability all techniques to identify the pivot points of the rotor both for reduced durations 
(2, 1, and 0.5 seconds) and spatial resolutions (32 x 32, 16 x 16, 8 x8 pixels). The MSF, Kt, and 
MSE had similarly high accuracies (greater than 90%) even as duration and spatial resolution 
decreased. However, the performance of SE was significantly lower with an accuracy less than 
70%.  
 
 
Figure 8.6 Accuracy of each technique to identify the stationary rotor from Figure 8.1A for reduced 
duration (A) and spatial resolution analysis (B). The top panels show accuracy calculated using the 
individual thresholds determined for the original 3s duration time series and 64x64 spatial 
resolution. Similar results are shown for the analysis using optimal thresholds (middle panel) and 
optimal accuracies (bottom panel). 
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8.4.2 Identification of Multiple Pivot Points in a Figure-of-8 Reentry 
A snapshot of the phase movie from a figure-of-8 reentry is shown in Figure 8.7A. Figure 8.7B 
shows the location of the singularity points (“true” location of the pivot points) identified from the 
phase movie. The red line indicates where the map was divided between meandering and stationary 
rotors. The top rotor, labeled ‘1,’ meanders while the bottom rotor remains stationary. Figure 8.7D 
shows representative filtered time series, power spectrums, and voltage intensity distributions from 
the pivot point of the meandering rotor and the periphery (pixels ‘1’ and ‘2’ respectively from 
8.7A).  
 
Figure 8.7 An example of multiple pivot points in a figure-of-8 reentry from optical mapping of a 
rabbit heart. (A) Snapshot of the phase movie for the figure-of-8 reentry, with the depolarizing 
wave front shown in red. The pivot point of the meandering rotor and periphery of the rotor are 
identified by ‘1’ and ‘2’ respectively. (B) Pixel map showing the “true” location of the pivot points 
of the meandering and stationary rotors identified from the phase movie. The red line indicates 
where the map was divided between meandering and stationary rotors. (C) 2D DF map from the 
figure-of-8 reentry showing a single DF of 8.1 Hz. (D) Representative examples of the time series, 
power spectrums, and voltage intensity distributions from the pivot point of the meandering rotor 
(location ‘1’) and the periphery (location ‘2’) of the rotors. 
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Figure 8.7C shows the corresponding 2D DF map calculated for the figure-of-8 reentry with a 
single DF = 8.1 Hz, which is unable to distinguish between the pivot points and the periphery in 
the figure-of-8 reentry. The 2D distributions of MSF, SE, Kt and MSE for the original figure-of-8 
reentry movie from Figure 8.7A (64 x 64 pixels, 3 seconds) are shown in Figure 8.8A. Each of the 
techniques is able to identify the meandering and stationary rotor separately from the periphery.  
 
8.4.2.1 Pivot Point Identification for Shorter Duration of Time Series 
The 3D contour plots in Figure 8.8B demonstrate the ability of MSF, SE, Kt and MSE to 
identify both the meandering and stationary rotors as the duration of the optical mapping movie is 
decreased. Similar to the stationary rotor example presented in Figure 8.4, the location of the pivot 
points can still be identified, but the peak becomes less prominent as the duration decreases. Note 
that the SE and MSE result in increased artifacts as the duration decreases, which strongly impacts 
the accuracy of the rotor identification for the SE and MSE approaches. From the 3D contour plots 
presented, both the MSF and Kt approaches provided clear identification of both rotors with 
minimal artifacts, even at an acquisition duration of 0.5 seconds.  
 
8.4.2.2 Pivot Point Identification for Reduced Spatial Resolution 
Figure 8.9 evaluates the ability of each technique to accurately identify multiple rotors under 
the simulated clinical limitation of reduced spatial resolution. As the spatial resolution decreases, 
the meandering rotor can still be identified. However, the stationary rotor can no longer be 
identified in the 8 x 8 pixel resolution (Figure 8.9, right panel). For this analysis, multiple pixels 
from the 8 x 8 analysis were recorded directly from the region of the meandering rotor, while no 
pixels were captured directly from the location of the stationary rotor.  
 
101 
 
 
Figure 8.8 (A) 2D maps calculated for the 3 sec optical mapping video of figure-of-8 reentry using 
MSF, SE, Kt, and MSE approaches. (B) 3D contour plots demonstrate the ability of each technique 
to identify multiple pivot points, the meandering and stationary rotors, for reduced arrhythmia 
durations of 2 sec, 1 sec, and 0.5 sec. The x and y coordinates correspond to (64x64) spatial 
resolution, and the z coordinate corresponds to the MSF, SE, Kt, and MSE values. 
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Figure 8.9 2D maps from MSF, SE, Kt, and MSE identifying the meandering and stationary rotors 
in the figure-of-8 reentry for reduced spatial resolutions of 32x32 (left), 16x16 (middle), and 8x8 
pixels (right). 
 
To quantitatively compare the results presented in Figures 8.8 and 8.9, the location of the pivot 
points for each approach were compared to the “true” location derived from the phase map. Figure 
8.10 presents the optimal accuracy of each approach for a reduced time series (Figure 8.10A) and 
spatial resolution (Figure 8.10B) in which optimized thresholds were used for each time series 
duration and each spatial resolution. The results are presented as two rotors combined (Figure 8.10, 
top panels) and then split into separate analysis for the meandering (Figure 8.10, middle panels) 
and stationary (Figure 8.10, bottom panels) rotor. The MSF, Kt, and MSE approaches all resulted 
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in high accuracies for identifying the pivot point of the rotors together and individually. High 
accuracies were maintained under simulated clinical limitations down to 16 x 16 pixels. However, 
the results of SE were significantly reduced, with the lowest accuracies less than 60% as the spatial 
resolution decreased.  
 
 
Figure 8.10 Optimal accuracy of each technique to identify the figure-of-8 from Figure 8.7A for 
reduced duration (A) and spatial resolution analysis (B). The optimal accuracies are shown for the 
combined rotors (top panel), the top, meandering rotor (middle panel), and the bottom, stationary 
rotor (bottom panel). 
 
8.5 DISCUSSION 
This study evaluated the robustness of the newly developed signal processing techniques to 
identify the pivot points of the rotors from optical mapping-based experiments. We also simulated 
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several clinical limitations, specifically reduced spatial resolution and acquisition duration. We 
used a simplified ventricular arrhythmia model in an ex-vivo heart to demonstrate the potential 
utility of these techniques in identifying stationary and meandering rotors. The major findings of 
the manuscript are the following:  
(1) MSF, Kt, and MSE were able to identify the rotor pivot point regardless of 
(i) progressively reduced acquisition time;  
(ii) decreased spatial resolution;  
(iii) the presence of meandering rotors;  
(2) MSE provided the highest accuracy for the signal stationary rotor;  
(3) the MSF approach had the highest accuracy overall for identifying both the stationary 
and meandering rotors in the figure-of-8 reentry;  
(4) the performance of SE approach was clearly diminished due to the large artifacts which 
reduced accuracy.   
The critical value of the results is that these approaches do not rely on repolarization 
information to pinpoint the rotor and its critical elements. Thus, it is possible that these 
mathematical approaches may be applied to clinically acquired electrogram data, which may be 
acquired over short time periods or with limited spatial density. Proving that data reflecting 
depolarization alone can be used to pinpoint rotor elements is a critical step in proving whether 
rotors can be accurately identified in clinical, human models of arrhythmia using currently available 
catheters and electrogram acquisition software.  
 
8.5.1 Efficacy of Each Technique 
In examples of both a single rotor and figure-of-8 reentry, the DF map resulted in a single 
frequency throughout the heart, making the pivot point of the rotor and its periphery 
indistinguishable. The MSF approach expands upon this frequency approach, which accounts for 
the chaotic nature at the rotor pivot point by incorporating underlying physiological frequencies in 
addition to the DF. This approach gave the most accurate localization of the pivot point in the event 
of both stationary and meandering rotors in the figure-of-8 reentry example. In addition, MSF 
maintained high accuracy even as the time series duration decreased.  
Both SE and Kt indices are based on the voltage intensity distribution and rely on the 
morphology of the electrical recordings, which significantly changes at the pivot point when 
compared to the periphery. This difference is reflected in the narrowing of the histogram at the 
pivot point of the rotor with a corresponding increase in the “peakedness” of the signal. The Kt 
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maps correctly identified the rotors in both examples, irrespective of time series duration and spatial 
resolution. However, the SE approach resulted in low contrast between the rotor and periphery 
reducing its accuracy.  
The MSE approach, which relies on the complexity of the electrical signal, was able to 
consistently differentiate the pivot point from the periphery. In the instance of a single rotor, the 
accuracy was the highest of the four techniques presented. In the presence of multiple rotors, MSE 
was able to identify both rotors, however, with a lower accuracy than the MSF approach.  
The next steps in this study will include characterizing the accuracy of these techniques in more 
complex experimental examples. Preliminary results shows the trajectory of the meandering rotor 
from a numerical simulation, which can be clearly identified using the MSF and MSE techniques. 
Figure 8.11 presents the analysis of a numerical simulation showing substantial meandering of a 
rotor in simulated human tissue (25mm x 25mm). The rotor trajectory for this example is shown in 
the upper right hand corner of the figure. The DF map below does not clearly identify the location 
of the rotor or its trajectory. The SE map shows the region through which the rotor traverses, but 
does not clearly show the trajectory and identifies a large portion of the periphery as part of the 
rotor. Finally the MSF, Kt, and MSE map show the most accurate rotor trajectories, with parts of 
the rotor path discernable in the final 2D maps. In addition, applying a variety of techniques to 
clinical examples of ventricular or atrial arrhythmias will assist in determining the reproducibility 
of the localization of specific rotors. Whether a single technique or combination of processing 
techniques using depolarization data from intracardiac electrograms may consistently and 
accurately characterize the location and critical components of rotors remains to be seen, though 
this work provides some further data on novel processing techniques that may facilitate these 
results.  
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Figure 8.11 2D maps calculated for a meandering rotor in a numerical simulation of human atrial 
tissue demonstrating the identification of the pivot point of the rotor using DF, MSF, SE, Kt, and 
MSE techniques. 
 
8.5.2 Clinical Translation 
Theories about the “cause and maintenance” of AF and, in turn, identifying optimal ablation 
targets continue to be an area of active debate. The theory regarding the relevance of rotors dates 
back to Gordon Moe [190], who noted the presence of organized regions of fundamental reentry 
may mediate AF (as contrasted with the multiple random wavelet and other hypotheses of the time). 
He also stated that it is unlikely that any one of these theories of how AF occurs is unlikely to stand 
alone. In fact, AF is likely a reflection of a variety of pathophysiologic processes – with the 
manifestation of AF on ECG (as an apparently random activity within the atria) being a complex 
process that may be subserved by any one of a number of pathophysiologic processes that may co-
exist in the same individual or be the primary mediator in a given individual. Thus, the scientific 
process to demonstrate that (1) a rotor exists; (2) these rotors play a principal role in AF 
propagation; and (3) that ablating these rotors actually has relevance to “curing” AF is inherently 
complex, particularly if it is possible for multiple mechanisms to co-exist or for the mechanism to 
vary between patients with inherently different substrates.  
That being said, invasive treatment of AF in humans still has major gaps. While true that data 
of additive approaches beyond pulmonary vein isolation (PVI) (e.g., linear lines, rotor ablation, 
complex fractionated electrogram ablation, autonomic ganglia ablation) have not consistently 
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shown benefit, debates continue to abound regarding patient selection and decision making on 
individualized approaches to the appropriate lesion set. Additionally, in many cases of AF, the best 
cases outcomes after multiple ablations in certain patients (e.g., persistent AF) continues to be in 
the 50-60% range.  
The principal question is, thus, whether currently available techniques that are used to make 
sense of the signals acquired during AF are sufficient to define “relevant substrate” or whether we 
should accept that all patients in whom PVI is ineffective must be subject to a lifetime of incurable 
AF, or whether a more “random” approach to treatment (e.g., empiric lines), or an approach that 
relies on targeting signals purely based on current methods of signal processing should be used.  
It is our belief that identifying better ways of processing the acquired signals during intracardiac 
mapping may help in further critically understanding relevant arrhythmic substrate to AF 
pathogenesis in individuals. Our findings demonstrate difference between various signal processing 
techniques in accurately and consistently defining seemingly organized zones of activity. In 
addition, current clinically available approaches may have limitations, such as with the DF 
approach, which points to the fact that the lack of success of additive approaches to AF ablation 
beyond PVI may be limited not simply due to “futility” of such approaches but also to lack of tools 
to adequately define the relevant areas.  
We further agree that any ablation, as much as it has the capacity to eliminate arrhythmia, also 
has the potential to create substrate for arrhythmia. This paper does not seek to say that these rotor 
zones will ultimately be the sites to target for ablation – instead they may represent zones of critical 
activity that may be targeted by other mechanisms or point to utility of specific types of 
antiarrhythmic medications based on their mechanism of action due to the presence of such rotors 
in specific individuals.  
Here, we have evaluated the potential utility of alternative signal processing approaches 
defining critical areas responsible for arrhythmia propagation. The use of less complex arrhythmia 
examples highlights the differences in the mathematical approaches presented here and showing 
potential to be further expanded to progressively more complex examples. Future work includes 
applying these approaches to (1) optically mapped examples of AF and VF and (2) 
comprehensively mapped clinical human examples of AF.  
 
8.5.3 Limitations  
This study is characterized by several limitations. First, these analyses were performed using 
data acquired through optical mapping in an experimental animal model of ventricular arrhythmia. 
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Thus, applicability of these analyses to intracardiac electrograms, which have variable filtering and 
localization methodologies, is unclear. In addition to the general limitations that are associated with 
obtaining the pivot point of the rotor is the dependence of the exact measurement locations in 
identifying the source of the arrhythmia. The optical mapping data has a high spatial resolution, 
and therefore the core of the rotor can be identified with a high accuracy. In simulating a reduction 
in spatial resolution, the results demonstrated that when measurements were not taken from the 
core, the rotor may not be identified. In the 8 x 8 pixel analysis of the figure-of-8 reentry example, 
the 2D mapping techniques were unable to identify the stationary rotor as there were no direct 
measurements taken from within the core.  
Another limitation of this study is the complexity of the arrhythmias analyzed. The optical 
mapping examples presented are on the lower end of complexity with uniform propagation through 
the tissue. In the presence of multiple wavebreaks, as occurs during AF, there will be additional 
complexity and irregularity in the electrical signals recorded which could affect the overall 
sensitivity and specificity of the mapping techniques presented. In addition, the data obtained from 
analysis of ventricular arrhythmias may not be directly applicable to atrial arrhythmias due to 
different atrial wall thickness and fundamental electrophysiological differences between these 
chambers. Finally, our examples of point acquisition during optical mapping are uniform. However, 
during intracardiac mapping, the points obtained may be affected by catheter orientation relative to 
the underlying myocardium, randomly distributed with clustering of points in specific areas, and 
include far field data from other structures. Thus, validation of these data when considering these 
increasing orders of complexity remains to be studied.  
 
8.6 CONCLUSION 
These results motivate further validation using intracardiac electrograms to determine if these 
approaches can identify pivot points in a clinical setting. It also highlights the potential utility of 
more experimental data in identifying which single technique or combination of techniques is 
necessary to accurately characterize rotors in various arrhythmia states. More accurate rotor 
localization could offer improved method of characterizing arrhythmias and, in turn, offer a means 
by which to more accurately study whether or not rotor ablation is a viable and effective treatment. 
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Chapter 9 
 
Part 2 Conclusions 
9.1 CONCLUSIONS 
Atrial fibrillation (AF) impacts 33.5 million people worldwide with diagnoses each year 
continuing to rise. Patients are often treated with pharmacological agents for the short-term 
management, to return the patient to normal sinus rhythm, and long-term management, to reduce 
AF-associated risks when the arrhythmia is unable to be controlled. Another treatment options for 
patients is catheter ablation to isolate the pulmonary veins, a region of increased ectopic activity 
and a possible source of the arrhythmia. For some patients, namely those with paroxysmal AF, this 
approach is relatively successful, terminating AF in approximately 7 out of 10 patients. However, 
for those with persistent AF or long-standing AF, this treatment approach has suboptimal success, 
with only 2 in 10 ablation procedures terminating the arrhythmia.  
One of the largest hurdles to appropriately targeting and subsequently terminating the 
arrhythmia in catheter ablation procedures is the lack of understanding of the spatial organization 
of AF. Multiple theories exists to explain the initiation and maintenance of arrhythmia, however 
the complex progression of AF and the large patient variability present significant challenges to 
clinically mapping the electrical activity in the atria. Numerous mapping techniques have been 
evaluated clinically to guide ablation procedures, but have not significantly improved patient 
outcomes. There is a clinical need for more accurate and robust mapping techniques to help enhance 
our understanding of the underlying spatial organization of the arrhythmia and to guide ablation 
procedures and ultimately improve outcomes.  
Here, we have evaluated the potential utility of alternative signal processing approaches 
defining critical areas responsible for arrhythmia propagation. Optical mapping studies were used 
to validate new signal processing techniques – multiscale frequency (MSF), kurtosis (Kt), Shannon 
entropy (SE), and multiscale entropy (MSE) – to identify regions of abnormal electrical activity. 
These studies allow for the visualization of electrical activity, both activation and recovery, in the 
heart through the use of voltage sensitive dye [242, 243], and allow for accurate localization of 
pivot point of rotors in episodes of fibrillation, providing a good platform for validating mapping 
techniques [201, 206].   
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Our findings reveal differences between various novel signal processing techniques in 
accurately and consistently identifying rotors or regions of functional reentry. These results 
demonstrate that MSF, Kt, and MSE accurately identified both stationary and meandering rotors, 
and these techniques remained accurate under simulated clinical limitations: shortened electrogram 
duration and decreased spatial resolution. In addition, the results demonstrate the limitations of the 
clinically available dominant frequency approach, which points to the fact that the lack of success 
of additive approaches to AF ablation beyond pulmonary vein isolation may be limited not simply 
due to “futility” of such approaches but also to lack of tools to adequately define the relevant areas. 
More accurate rotor localization could offer improved method of characterizing arrhythmias and, 
in turn, offer a means by which to more accurately study whether or not rotor ablation is a viable 
and effective treatment. 
The use of less complex arrhythmia examples from optical mapping studies highlights the 
differences in the mathematical approaches presented here and allows for validation of rotor 
identification. Further, the examples presented show potential to be further expanded to 
progressively more complex examples in simulated arrhythmias and clinical intracardiac 
electrograms. These results also highlight the potential utility of more experimental data in 
identifying which single technique or combination of techniques is necessary to accurately 
characterize rotors in various arrhythmia states.  
 
9.2 FUTURE WORK 
Further research in this area is necessary to translate and validate these techniques for clinical 
studies where unipolar and bipolar intracardiac electrograms are used to evaluate and guide ablation 
for AF patients. First, future work will apply these novel techniques to more complex arrhythmias 
in experimental and simulated cardiac arrhythmia examples. Converting transmembrane voltage 
signals to equivalent unipolar and bipolar electrogram recordings can provide an indication of 
whether the techniques will be effective in identifying rotors in a different representation of the 
cardiac electrical signal. In addition, further research may reveal that a combination of mapping 
techniques provides more accurate rotor localization compared to a single mapping technique 
alone. These studies will allow for further validation of these techniques prior to implementation 
in a clinical setting.  
Once validated, future studies will apply these techniques to recorded intracardiac electrograms 
recorded in patients with paroxysmal and non-paroxysmal AF both before and after ablation to 
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evaluate whether the new mapping techniques could successfully predict arrhythmia termination 
based on pre- and post-ablation recordings. With successful implementation of these novel mapping 
techniques, the ultimate goal is to integrate these techniques with current mapping system to 
evaluate arrhythmias in real-time and guide ablation therapy to improve the percentage of patients 
who are arrhythmia free after ablation procedures.    
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Appendix A 
Techniques 
 ANIMAL SURGICAL PROCEDURES 
All experiments were approved by the University of Minnesota Animal Care and Use 
Committee and were conducted in accordance with Institutional and NIH guidelines (NIH 
publication No. 85-23, revised 1996). 
 
Vagus Nerve Stimulator Implantation 
VNS stimulators were implanted subcutaneously on the lower back of the rats as described 
previously [125, 126]. Briefly, the back and the neck were shaved, and the right cervical vagus 
nerve and common carotid artery bundle were isolated from the surrounding tissue through a small 
incision on the neck. Bipolar cuff electrodes were placed around the bundle. The pulse generator 
(8 cc, 14 g) was then implanted subcutaneously and positioned on the back of the rat. Parameters 
of the intermittent VNS for the study presented in Chapter 3 were set as follows: pulse frequency 
20 Hz; pulse width 500 μs; output current 1.0 mA. The VNS therapy was delivered with a duty 
cycle of 15% with VNS on for 7 s followed by 66 s of VNS off. Parameters for VNS in the study 
presented in Chapters 4 and 5 were set as follows: pulse frequency 20 Hz; pulse width 500 μs; 
output current set individually for each rat resulting in a heart rate drop of no more than 5% while 
VNS in on. The VNS therapy was delivered with a duty cycle of 23% with VNS on for 14 s followed 
by 66 s of VNS off. Note each episode of VNS includes a 2-second ramp up and ramp down which 
are part of the 66 sec “Off” period but included in the “On” period for duty cycle calculations. 
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DSI Telemetry System Implantation 
The DSI transmitter implantation was performed as described previously48. Briefly, the surgical 
regions, the chest and inner leg, were shaved and the transmitter pressure catheter was implanted 
into the descending aorta through the left femoral artery. The two ECG leads were fixed 
subcutaneously on the chest muscle. Following recovery, the rats were conscious and freely moving 
in their home cage for the duration of the in-vivo study. Continuous arterial blood pressure and 
ECG data acquisitions were performed at a sampling rate of 500 Hz with the use of commercially 
available telemetry system (DSI, Inc.). Each cage is placed on a receiver (Model RPC1, DSI Inc.) 
that was connected to a computer via a Data Exchange Matrix (DSI Inc.). 
 
 OPTICAL MAPPING 
At the end of the in-vivo protocol, the rats were sacrificed and the hearts were extracted through 
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a thoracotomy for ex-vivo optical mapping studies. The hearts were cannulated through the aorta 
and Langendorff-perfused using a warm (37 +/- 1 °C), oxygenated Tyrode’s solution (in mM: NaCl 
130, CaCl2 1.8, KCl 4, MgCl2, 1.0, NaH2PO4 1.2, NaHCO3 24, C6H12O6 5.5, pH 7.4) under 
constant pressure [128]. Blebbistatin (10 μM) was added to the Tyrode’s solution to reduce motion 
artifact and voltage sensitive dye, Di4-ANNEPS, was added (5 μg/mL) to the perfusate. The dye 
was excited using two continuous-excitation lasers with a wavelength of 532nm (Millenia Pro 5sJ, 
Spectra-Physics Inc., Mountain View, CA, USA). The voltage/action potentials from the epicardial 
surface of both ventricles were captured using two synchronized 14-bit CCD cameras (Little Joe 
CCD39, SciMeasure Analytical Systems Inc., GA, USA). The cameras captured the cardiac 
electrical signal at a rate of 1000 frames per second with 80x80 pixel resolution from approximately 
80% of the ventricular surface.   
The hearts were then paced to assess the electrophysiological changes during sinus rhythm, 
periodic pacing, and through VF induction. The HTN hearts were paced at a progressively 
decreasing basic cycle length (BCL), from 200 down to 100 ms in steps of 20 ms then from 90 ms 
down to 60 ms in steps of 10 ms or until ventricular tachycardia (VT) or ventricular fibrillation 
(VF) induction. At each BCL, 50 stimuli were applied to reach steady state, and the last 10 stimuli 
were recorded for analysis. If the hearts did not exhibit VT or VF during the dynamic pacing 
protocol, the VT/VF induction protocol was used.  
 
Optical Mapping Analysis 
Using the optical mapping videos, the following parameters regarding the electrophysiological 
properties of the Sham and VNS hearts were calculated at varying BCLs for both the right ventricle 
(RV) and left ventricle (LV) as previously described [128, 240]: action potential duration (APD), 
spatial heterogeneity of APD, slope of APD restitution, conduction velocity (CV), and VT/VF 
analysis. 
 
APD: optical APD was measured at 80% repolarization (APD80) and 2D maps were constructed to 
observe the spatial distribution of APDs on the epicardial surface of the RV and LV. 
 
Spatial heterogeneity of APD: Spatial distribution of APD was estimated using the heterogeneity 
index, μ50. This index was calculated as follows:  
𝜇 =
𝐴𝑃𝐷95 − 𝐴𝑃𝐷5
𝐴𝑃𝐷50
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Where APD95 and APD5 are the 95th and 5th percentiles of the APD distribution respectively 
and APD50 is the median APD distribution.  
 
Slope of APD restitution: At each pixel, the maximum slope of the APD restitution curve was 
calculated using a results from the dynamic pacing protocol. 2D slope maps were obtained for the 
RV and LV separately. These maps were used to compare arrhythmia susceptibility between the 
treated and untreated groups.  
 
Conduction velocity: The local CV was measured as described previously50. The distributions of 
activation times for the spatial regions of 5x5 pixels were fitted to a plane. Gradients of activation 
times, gx and gy, were calculated for the plane along the x and y axes respectively. The magnitude 
of the local CV was calculated for each pixel as: 
𝐶𝑉 =
1
√𝑔𝑥
2 + 𝑔𝑦
2
 
Mean values and standard errors of CV were recorded at each BCL for the RV and LV.  
 
VT/VF analysis:  Episodes of VT or VF were captured using optical mapping. Three second videos 
of VT or VF were recorded and used to analyze the complexity of the cardiac arrhythmias in the 
Sham and VNS hearts. These episodes were evaluated to determine the number of domains and the 
corresponding DF for each domain by constructing 2D DF maps of the LV and RV.   
